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Changes in potential regulatory elements are thought to be key drivers of phenotypic
divergence. However, identifying changes to regulatory elements that underlie human-
specific traits has proven very challenging. Here, we use 63 reconstructed and experimentally
measured DNA methylation maps of ancient and present-day humans, as well as of six
chimpanzees, to detect differentially methylated regions that likely emerged in modern
humans after the split from Neanderthals and Denisovans. We show that genes associated
with face and vocal tract anatomy went through particularly extensive methylation changes.
Specifically, we identify widespread hypermethylation in a network of face- and voice-
associated genes (SOX9, ACAN, COL2A1, NFIX and XYLT1). We propose that these repression
patterns appeared after the split from Neanderthals and Denisovans, and that they might
have played a key role in shaping the modern human face and vocal tract.
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The advent of high-coverage ancient genomes of archaichumans (Neanderthal and Denisovan) introduced thepossibility to identify the genetic basis of some unique
modern human traits1. A common approach is to carry out
sequence comparisons and detect non-neutral sequence changes.
However, out of ~30,000 substitutions and indels that reached
fixation in modern humans, less than 100 directly alter amino
acid sequence1, and as of today, our ability to estimate the bio-
logical effects of the remaining ~30,000 noncoding changes is
very restricted. Whereas many of them are probably nearly
neutral, many others may affect gene function, especially those in
regulatory regions such as promoters and enhancers. Such
changes in regulatory elements may have a sizeable impact on
human evolution, as alterations in gene regulation are thought to
underlie much of the phenotypic variation between closely related
groups2. Because of the limited ability to interpret noncoding
variants, direct examination of regulatory layers such as DNA
methylation has the potential to enhance our understanding of
the evolutionary origin of human-specific traits far beyond what
can be achieved using sequence comparison alone3.
In order to gain insight into changes in regulatory elements
that might underlie human evolution, we previously developed a
method to reconstruct DNA methylation maps of ancient gen-
omes based on analysis of patterns of damage to ancient DNA4.
We used this method to reconstruct the methylomes of a
Neanderthal and a Denisovan, which were then compared to a
partial methylation map of a present-day osteoblast cell line.
However, the ability to identify differentially methylated regions
(DMRs) between the human groups was constrained by the
incomplete reference map (providing methylation information
for ~10% of CpG sites), differences in outputs of sequencing
platforms, lack of an outgroup, and a restricted set of skeletal
samples (see Supplementary Methods).
To study the evolutionary dynamics of DNA methylation along
the hominin tree on a larger scale, here we use 69 skeletal DNA
methylation maps from modern humans, archaic humans, and
chimpanzees to identify 588 genes whose methylation state is
unique to modern humans. We then analyze the function of these
genes by investigating their known anatomical effects, and vali-
date this using over 50 orthogonal tests and controls. We find that
the most extensive DNA methylation changes are observed in
genes that affect vocal and facial anatomy, and that this trend
appears to be unique to modern humans.
Results
Generating DNA methylation maps. We reconstructed ancient
DNA methylation maps of eight individuals: in addition to the
previously published Denisovan and Altai Neanderthal methyla-
tion maps4, we reconstructed the methylomes of the Vindija
Neanderthal (~52 thousand years ago, kya)5, and three anatomi-
cally modern humans: the Ust'-Ishim individual (~45 kya, Wes-
tern Siberia)6, the Loschbour individual (~8 kya, Luxemburg)7,
and the Stuttgart individual (~7 kya, Germany)7. We also
sequenced to high-coverage and reconstructed the methylomes of
the La Braña 1 individual from Spain (~8 kya, 22×) (which was
previously sequenced to low-coverage)8 and an individual from
Barçın Höyük, Western Anatolia, Turkey (I1583, ~8.5 kya, 24×),
which was previously sequenced using a capture array9.
To this set we added 52 publicly available partial bone
methylation maps from present-day individuals, produced using
450K methylation arrays (see Supplementary Methods). To
obtain full present-day bone maps, we produced whole-genome
bisulfite sequencing (WGBS) methylomes from the femur bones
of two individuals (Bone1 and Bone2, Supplementary Fig. 1).
Hereinafter, ancient and present-day modern humans are
collectively referred to as anatomically modern humans (AMHs),
while the Neanderthal and Denisovan are referred to as archaic
humans. As an outgroup, we produced methylomes of six
chimpanzees: one WGBS, one reduced representation bisulfite
sequencing (RRBS) and four 850K methylation arrays (Supple-
mentary Fig. 1, Supplementary Tables 1, 2). Together, these data
establish a unique and comprehensive platform to study DNA
methylation dynamics in recent human evolution (Supplemen-
tary Data 1).
Identification of DMRs. We developed a DMR-detection
method for ancient methylomes, which accounts for potential
noise introduced during reconstruction, as well as differences in
coverage and deamination rates. To minimize the number of false
positives and to identify DMRs that are most likely to have a
regulatory effect, we applied a strict threshold of >50% difference
in methylation across a minimum of 50 CpGs. This also filters out
environmentally-induced DMRs which typically show small
methylation differences and limited spatial scope10. Using this
method, we identified 9679 regions overall that showed methy-
lation differences between any of the high-quality representative
methylomes of the Denisovan, the Altai Neanderthal, and the
Ust’-Ishim anatomically modern human. These regions do not
necessarily represent evolutionary differences between the human
groups. Rather, many of them could be attributed to variability
within populations or to factors separating the three individuals
(e.g., Ust’-Ishim is a male whereas the archaic humans are
females). One common approach to minimize such false positives
is to match samples in as many parameters as possible: age, sex,
bone type, technology, and disease state. However, this is rarely
fully accomplished, and samples often remain unmatched in one
or more categories. A stricter approach is to leverage the varia-
bility between samples to estimate the maximum contribution of
their confounders. To this end, and to minimize the contribution
of within-population variability, we used the 59 additional human
maps to filter out regions where variability in methylation is
detected. Importantly, our samples come from both sexes, from
individuals of various ages and ancestries, from patients and
healthy individuals, and from a variety of skeletal parts (femur,
skull, phalanx, tooth, and rib). We adopted a conservative
approach, whereby we take only loci where methylation in one
hominin group is found completely outside the range of methy-
lation in the other groups (Fig. 1a). Hence, as the differences
between groups is considerably larger than the contribution of
these factors, this procedure is expected to account for these
potentially confounding factors, and the remaining DMRs are
expected to represent true evolutionary differences (Fig. 1a–c and
Supplementary Figs. 2, 3, Supplementary Methods). This step
resulted in a set of 7649 DMRs that discriminate between the
human groups, which we ranked according to their significance
level. For the top candidates (see later), we also ascertain that the
differential methylation is observed when matching samples from
the same bone type, age, disease state, and technology.
Next, using the chimpanzee samples, we were able to
determine for 2825 of these DMRs the lineage where the
methylation change occurred (Fig. 1d). Of these DMRs, 873 are
AMH-derived, 939 are archaic-derived, 443 are Denisovan-
derived, and 570 are Neanderthal-derived (Fig. 2a and Supple-
mentary Fig. 3, Supplementary Data 2). To study the derived
biology of AMHs, and to focus on DMRs that are based on the
most extensive set of maps, we concentrated on the 873 AMH-
derived DMRs. We found that these DMRs are located 58× closer
to AMH-derived sequence changes than expected by chance
(0.092Mb vs. a median of 5.3 Mb, P < 10−5, permutation test,
Fig. 2b). This suggests that some of the methylation changes
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might be associated with cis-regulatory sequence variants that
arose along the AMH lineage.
Face and voice-associated genes are derived in AMHs. We
defined differentially methylated genes (DMGs) as genes that
overlap at least one DMR along their body or in their promoter,
up to 5 kb upstream. The 873 AMH-derived DMRs are linked to
588 AMH-derived DMGs (Supplementary Data 2). To gain
insight into the function of these DMGs, we first analyzed their
gene ontology (GO). As expected from genes that show differ-
ential methylation in the skeleton between human groups, AMH-
derived DMGs are enriched with terms associated with the
450 K WGBS Recon. 850 K WGBSRecon. Recon.
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skeleton (e.g., endochondral bone morphogenesis, trabecula
morphogenesis, and palate development). Also notable are terms
associated with the muscular, cardiovascular, and nervous sys-
tems (Supplementary Data 3).
To acquire a more precise understanding of the possible
functional consequences of these DMGs, we used Gene
ORGANizer, which links human genes to the organs they
phenotypically affect11. Unlike tools that use GO terms or RNA
expression data, Gene ORGANizer is based entirely on curated
gene-disease and gene-phenotype associations from monogenic
diseases. It relies on direct phenotypic observations in human
patients whose conditions are associated with known gene
Fig. 1 Variability filtering and lineage assignment. a Methylation levels across AMH, Denisovan, Neanderthal, and chimpanzee samples in DMR#278
(chr4:38,014,896–38,016,197). This is an example of a lineage-specific DMR, defined as a locus in which all samples of a group are found outside the range
of methylation in the other groups. Chimpanzee samples were used during the following step of lineage assignment. b A putative limb-specific DMR
(chr3:14,339,371–14,339,823) which was removed from the analysis, as it does not comply with our definition of lineage-specific DMRs. Femur, toe, and
finger samples are hypermethylated compared to other skeletal elements. Toe and finger are found at the bottom range of limb samples, suggesting some
variation in this locus within limb samples too. c A putative sex-specific DMR (chr3:72,394,336–72,396,901) which was removed from the analysis. Males
are hypermethylated compared to females. d Lineage assignment using chimpanzee samples. Only DMRs that passed the previous variability filtering steps
were analyzed. Each bar at the tree leaves represents a locus in a sample. Methylation levels of the locus in each sample are marked with red (methylated)
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Fig. 2 Genes affecting voice and face are the most over-represented within AMH-derived DMRs. a The number of DMRs that emerged along each of the
human branches. Divergence times are in thousands of years ago (kya). b Distribution of median distances (turquoise) of DMRs to randomized single
nucleotide changes that separate AMHs from archaic humans and chimpanzees. Genomic positions of single nucleotide changes were allocated at random.
This was repeated 10,000 times. Red arrow marks the observed distance of DMRs, showing that they tend to be significantly closer to AMH-derived single
nucleotide changes than expected by chance. This suggests that some of these sequence changes might be associated with the changes in methylation. c A
heat map representing the level of enrichment of each anatomical part within the AMH-derived DMRs. Only body parts that are significantly enriched
(FDR < 0.05) are colored. Three skeletal parts are significantly over-represented: the face, pelvis, and larynx (voice box, marked with arrows). d Enrichment
levels of anatomical parts within the most significant (top quartile, Q statistic) AMH-derived DMRs, showing a more pronounced enrichment of genes
affecting vocal and facial anatomy.
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perturbations. Hereinafter, we refer to genes as associated with an
organ if they have been shown to have a phenotypic effect on that
organ in patients where this gene is dysfunctional. An enrichment
or depletion in Gene ORGANizer is detected if the group of genes
analyzed shows a significant deviation in the organs they are
known to phenotypically affect, compared to the rest of the
genome. Using Gene ORGANizer, we found 11 organs that are
over-represented within the 588 AMH-derived DMGs, eight of
which are skeletal parts that can be divided into three regions: the
face, larynx (voice box), and pelvis (Fig. 2c and Supplementary
Data 4). The strongest enrichment was observed in the laryngeal
region (×2.11 and ×1.68, FDR= 0.017 and 0.046, for the
vocal folds (vocal cords) and larynx, respectively), followed by
facial and pelvic structures, including the teeth, forehead, jaws,
and pelvis. Interestingly, the face and pelvis are considered the
most morphologically divergent regions between Neanderthals
and AMHs12 and our results reflect this divergence through gene
regulation changes. To gain orthogonal evidence for the
enrichment of the larynx and face within these AMH-derived
DMGs, we carried out a number of additional analyses: First, we
analyzed gene expression patterns and found that the supralar-
yngeal vocal tract (the pharyngeal, oral, and nasal cavities, where
sound is filtered to specific frequencies) is the most enriched body
part (1.7× and 1.6×, FDR= 5.6 × 10−6 and FDR= 7.3 × 10−7, for
the pharynx and larynx, respectively, hypergeometric test,
Supplementary Data 3). Second, 44 of the AMH-derived DMRs
overlap previously reported putative enhancers of human
craniofacial developmental genes (5.1× compared to expected,
P < 10−4, permutation test)13,14. Third, Palate development is the
third most enriched GO term among AMH-derived DMGs
(Supplementary Data 3). Fourth, DMGs significantly overlap
genes associated with craniofacial features in the GWAS catalog15
(P= 3.4 × 10−4, hypergeometric test).
To test whether this enrichment remains if we take only the
most confident DMRs, we limited the analysis to DMGs where
the most significant DMRs are found (top quartile, Q statistic).
Here, the over-representation of voice-affecting genes is even
more pronounced (2.82× and 2.26×, for vocal folds and larynx,
respectively, FDR= 0.028 for both, Fig. 2d and Supplementary
Data 4).
Next, we reasoned that skeleton-associated genes might be
over-represented in analyses that compare bone DNA methyla-
tion maps, hence introducing potential biases. To test whether
this enrichment might explain the over-representation of the
larynx, face, and pelvis, we compared the fraction of genes
associated with these organs within all skeletal genes to their
fraction within the skeletal genes in the AMH-derived DMGs. We
found that genes associated with the face, larynx, and pelvis are
significantly over-represented even within skeletal AMH-derived
DMGs (P= 1.0 × 10−5, P= 1.3 × 10−3, P= 2.1 × 10−3, P= 0.03,
for vocal folds, larynx, face, and pelvis, respectively, hypergeo-
metric test). Additionally, using a permutation test, we found that
the enrichment levels within AMH-derived DMGs are signifi-
cantly higher than expected by chance for the laryngeal and facial
regions, but not for the pelvis (P= 8.0 × 10−5, P= 3.6 × 10−3,
P= 8.2 × 10−4, and P= 0.115, for vocal folds, larynx, face and
pelvis, respectively, permutation test, Supplementary Fig. 4,
Supplementary Methods). Thus, we found that the enrichment
in the facial and laryngeal regions is not a by-product of a general
enrichment in skeletal parts, and we hereinafter focus on genes
associated with these two regions.
Finally, we ruled out the options that our DMR-detection
algorithm, number of samples, filtering process or biological
factors such as gene length, cellular composition, pleiotropy or
developmental stage might underlie the enrichment of these
organs (see Supplementary Methods). Perhaps most importantly,
none of the other branches shows enrichment of the larynx or the
vocal folds; Neanderthal-derived and Denisovan-derived DMGs
show no significant enrichment in any organ, and archaic-derived
DMGs are over-represented in the jaws, lips, limbs, scapulae, and
spinal column, but not in the larynx or vocal folds (Supplemen-
tary Fig. 4e, Supplementary Data 4). In addition, DMRs that
separate chimpanzees from all humans (archaic and modern,
Supplementary Data 2) do not show enrichment of genes
associated with the larynx or face, compatible with the notion
that this trend emerged along the AMH lineage.
Taken together, we conclude that DMGs that emerged along
the AMH lineage are uniquely enriched in genes associated with
the voice and face, and that this is unlikely to be an artifact of (a)
inter-individual variability resulting from age, sex, disease, or
bone type; (b) significance level of DMRs; (c) the reconstruction
or DMR-detection processes; (d) number of samples used; (e)
pleiotropic effects; (f) the types of methylation maps used; (g) the
comparison of skeletal methylomes; (h) gene length distribution;
or (i) biological factors such as cellular composition and
developmental state.
Our analyses identified 56 DMRs in genes associated with the
facial skeleton, and 32 in genes associated with the laryngeal
skeleton. The face- associated genes are known to shape mainly
the protrusion of the lower and midface, the size of the nose, and
the slope of the forehead. Interestingly, these traits are considered
some of the most derived between Neanderthals and AMHs12.
The larynx-associated genes have been shown to underlie various
phenotypes in patients, ranging from slight changes to the pitch
and hoarseness of the voice, to a complete loss of speech ability11
(Supplementary Data 5). These phenotypes were shown to be
driven primarily by alterations to the laryngeal and vocal tract
skeleton. Methylation patterns in differentiated cells are often
established during earlier stages of development, and the closer
two tissues are developmentally, the higher the similarity between
their methylation maps3,16,17. This is also evident in the fact that
DMRs identified between species in one tissue often exist in other
tissues as well16. Importantly, the laryngeal skeleton, and
particularly the arytenoid cartilage to which the vocal folds are
anchored, share an origin from the somatic layer of the lateral
plate mesoderm with the cartilaginous tissue of the limb bones
prior to their ossification. Thus, it is likely that many of the DMRs
identified here between limb samples also exist in their closest
tissue—the laryngeal skeleton. This is further supported by the
observation that these DMGs are consistent across all examined
skeletal samples, including skull, femur, rib, tibia, and tooth.
Furthermore, we directly measured methylation levels in a subset
of the DMRs in primary chondrocytes and show that their
patterns extend to these cells as well (see below).
Extensive changes within face and voice-associated genes. The
results above suggest that methylation levels in many face-
associated and voice-associated genes have changed in AMHs
since the split from archaic humans, but they do not provide
information on the extent of changes within each gene. To do so,
we scanned the genome in windows of 100 kb and computed the
fraction of CpGs which are differentially methylated in AMHs
(hereinafter, AMH-derived CpGs). We found that the extent of
changes within voice-associated DMGs is most profound, more
than 2× compared to other DMGs (0.132 vs. 0.055, FDR= 2.3 ×
10−3, t-test, Supplementary Data 6). Face- associated DMGs also
present high density of AMH-derived CpGs (0.079 vs. 0.055,
FDR= 2.8 × 10−3, t-test). In archaic-derived DMGs, on the other
hand, the extent of changes within voice-associated and face-
associated genes is not different than expected (FDR= 0.99,
t-test, and Supplementary Data 6). To control for possible biases,
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we repeated the analysis using only the subset of DMRs in genes
associated with the skeleton. Here too, we found that voice-
associated AMH-derived DMGs present the highest density of
changes (2.5× for vocal folds, 2.4× for larynx, FDR= 1.4 × 10−3
for both, t-test, Supplementary Data 6), and face-associated
DMGs also exhibit a significantly elevated density of changes
(1.4×, FDR= 0.04, t-test).
We also found that compared to other AMH-derived DMRs,
DMRs in voice-associated and face-associated genes tend to
be 40% closer to candidate positively selected loci in AMHs18
(P < 10−4, permutation test).
Strikingly, when scanning the genome for hotspots of
methylation changes, all top five skeleton-related loci are found
within genes known to associate with lower and midfacial
protrusion, as well as the voice (ACAN, SOX9, COL2A1, XYLT1,
and NFIX)11,19 (Fig. 3 and Supplementary Fig. 4f). This is
particularly surprising considering that genome-wide, less than
2% of genes (345) are known to affect the voice, ~3% of genes
(726) are known to associate with lower and midfacial protrusion,
and less than 1% (182) are known to associate with both11,19.
The three skeletal DMGs with the highest density of AMH-
derived CpGs are the extra-cellular matrix genes ACAN and
COL2A1, and their key regulator SOX9, which together form a
network that regulates skeletal growth, the transition from
cartilage to bone, and spatio-temporal patterning of skeletal
development, including the facial and laryngeal skeleton in
humans19,20 and mouse21. SOX9 was also shown to be one of the
top genes associated with variation in craniofacial morphology
within-AMHs22. SOX9 is regulated by a series of upstream
enhancers identified in mouse and human23. In human skeletal
samples, hypermethylation of the SOX9 promoter was shown to
downregulate its activity, and consequently its targets24. This was
also demonstrated repeatedly in non-skeletal tissues of
human25,26 and mouse27,28. We found substantial hypermethyla-
tion in AMHs in the following regions: (a) the SOX9 promoter;
(b) seven of its proximal and distal skeletal and skeletal
progenitor enhancers23; (c) the targets of SOX9: ACAN (DMR
#80) and COL2A1 (DMR #1, the most significant AMH-derived
DMR, which spans 32 kb and covers almost the entire COL2A1
gene, from its 1st intron to its 54th exon and 3′UTR region); and
(d) an upstream lincRNA (LINC02097). Notably, regions (a), (b),
and (d) overlap the longest DMR on the AMH-derived DMR list,
spanning 35,910 bp (DMR #11, Fig. 4). Additionally, a more
distant putative enhancer, located 345 kb upstream of SOX9, was
shown to bear strong active histone modification marks in
chimpanzee craniofacial progenitor cells; whereas, in humans
these marks are almost absent (~10× lower than chimpanzee,
suggesting downregulation, Fig. 4b)13. Importantly, human and
chimpanzee non-skeletal tissues (i.e., brain and blood) exhibit
very similar methylation patterns in these genes, suggesting the
DMRs are skeleton-specific. Finally, the amino acid sequence
coded by each of these genes is identical across the hominin
groups1, suggesting that the observed changes are purely
regulatory. Together, these observations support the idea that
SOX9 became downregulated in AMH skeletal tissues, likely
followed by downregulation of its targets: ACAN and COL2A1.
XYLT1, the 4th highest skeleton-related DMG, is an enzyme
involved in the synthesis of glycosaminoglycan. Loss-of-function
mutations, hypermethylation of the gene and its consequent
reduced expression underlie the Desbuquois dysplasia skeletal
syndrome, which was shown to affect the cartilaginous structure
of the larynx, and drive a retraction of the face29,30. Very little
is known about XYLT1 regulation, but interestingly, in zebrafish
it was shown to be bound by SOX9 (ref. 31).
To quantitatively investigate the potential phenotypic con-
sequences of these DMGs, we tested what fraction of their known
phenotypes are also known as traits that differ between modern
and archaic humans. We found that four of the top five most
differentially methylated genes (XYLT1, NFIX, ACAN, and
COL2A1) are in the top 100 genes with the highest fraction of
divergent traits between Neanderthals and AMHs. Remarkably,
COL2A1, the most divergent gene in its methylation patterns, is
also the most divergent in its phenotypes: no other gene in the
genome is associated with as many divergent traits between
modern humans and Neanderthals32 (63 traits, Supplementary
Data 7, see Supplementary Methods). This suggests that these
extensive methylation changes are possibly linked to phenotypic
divergence between archaic and AMHs.
NFIX methylation patterns suggest downregulation in AMHs.
In order to investigate how methylation changes affect expression
levels, we scanned the DMRs to identify those whose methylation
levels are strongly correlated with expression across 22 human
tissues33. We found 90 such AMH-derived DMRs (FDR < 0.05,
Supplementary Data 2). DMRs in voice-associated genes are
significantly more likely to be correlated with expression com-
pared to other DMRs (2.05×, P= 6.65 × 10−4, hypergeometric
test). Particularly noteworthy is NFIX, one of the most derived
genes in AMHs (ranked 5th among DMGs affecting the skeleton,
Fig. 3a, b). NFIX contains two DMRs (#24 and #167, Fig. 5a), and
in both, methylation levels are tightly linked with expression
(correlation of 81.7 and 73.8%, FDR= 3.5 × 10−6 and 8.6 × 10−5,
respectively, Pearson’s r, Fig. 5b). In fact, NFIX is one of the top
ten DMGs with the most significant correlation between
methylation and expression in human. The association between
NFIX methylation and expression was also shown previously
across several mouse tissues34,35. To further examine this, we
investigated a dataset of DNMT3A-induced methylation of
human MCF-7 cells. Forced induction of methylation in this
study was sufficient to repress NFIX expression by over 50%,
placing NFIX as one of the genes whose expression is most
affected by hypermethylation36 (ranked in the 98th percentile,
FDR= 1.28 × 10−6). We further validated the hypermethylation
of NFIX across the skeleton by comparing four human cranial
samples to four chimpanzee cranial samples through bisulfite-
PCR (P= 0.01, t-test, Supplementary Fig. 5, Supplementary
Data 1, Supplementary Table 3, Supplementary Methods).
Together, these findings suggest that the observed hypermethy-
lation of NFIX in AMHs reflects downregulation that emerged
along the AMH lineage. Indeed, we found that NFIX, as well as
SOX9, ACAN, COL2A1, and XYLT1 are hypermethylated in
human femora compared to baboon37 (P= 1.4 × 10−5 and P=
8.1 × 10−9, compared to baboon femora bone and cartilage,
respectively, t-test). Also, all five genes show significantly reduced
expression in humans compared to mice (Fig. 5c). Taken toge-
ther, these observations suggest that DNA methylation is a pri-
mary mechanism in the regulation of NFIX, and serves as a good
proxy for its expression. Interestingly, NFI proteins were shown
to bind the upstream enhancers of SOX9 (ref. 38), hence sug-
gesting a possible mechanism to the simultaneous changes in the
five top genes we report.
Discussion
We have shown here that genes associated with vocal and facial
anatomy have different DNA methylation patterns in recent
AMH, compared to Neanderthals and Denisovans. The differ-
ences in DNA methylation are manifested both in the number of
divergent genes and in the extent of changes within each gene.
Notably, the DMRs we report capture substantial methylation
changes (over 50% between at least one pair of human groups),
span thousands or tens of thousands of bases, including in
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promoters and enhancers. Many of these methylation changes are
associated with changes in expression. We particularly focused on
changes that might affect regulation of the five most derived
skeletal genes on the AMH lineage: SOX9, ACAN, COL2A1,
XYLT1, and NFIX, whose downregulation was shown to underlie
a retracted face, as well as changes to the structure of the
larynx20,29,39–42. The results we report, which are based on
ancient DNA methylation patterns, provide means to analyze the
genetic mechanisms that underlie the evolution of the human face
and vocal tract.
One of the limitations of analyzing regulatory maps is their
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technology-specific patterns. Although the vast majority of loci
show stable patterns regardless of these factors, some loci are
nevertheless affected by them43. Perfectly matching two human
samples across all of these factors is rarely achievable. Therefore,
we used a stricter approach, which results in fewer discoveries,
but is able to leverage the variability introduced by tissue, sex, age,
disease, and technology to identify loci where these factors are
unlikely to underlie the observed methylation differences. For the
top candidates, we also matched samples for these factors and
showed that the differential methylation is still observed.
A central confounder of reconstructed methylation maps is
their resolution. Although their resolution is substantially better
than that of methylation arrays, it is still inferior to that of WGBS.
Both WGBS and ancient reconstruction rely on the same process
to measure methylation: deamination of cytosines. However, in
WGBS, the use of bisulfite results in ~99% deamination rate,
whereas in ancient reconstruction the average rate is usually
lower than 5%43. To account for this, we used a window of 25
CpGs, which increases power at the cost of resolution. Therefore,
in this study, we are only able to detect DMRs that are larger than
the window used. To detect more subtle changes, genomes with
higher deamination rates, or merging several genomes together
are required.
Humans are distinguished from other apes in their unique
capability to communicate through speech. This capacity has
been attributed not only to neural changes, but also to config-
urational alterations to the vocal tract44, as humans have a larynx
that is located particularly low among primates44 (Fig. 6a), and
Fig. 3 The extent of differential methylation is highest among genes associated with the voice. a Within each lineage, the fraction of differentially
methylated CpGs was computed as the number of derived CpGs per 100 kb centered around the middle of each DMR. DMRs were ranked according to the
fraction of derived CpG positions in their vicinity. DMRs in genes associated with the voice are marked with red lines. In AMHs, DMRs in voice-affecting
genes tend to be ranked significantly higher. Although known voice-associated genes comprise less than 2% of the genome, three of the top five AMH-
derived DMRs, and all top five skeleton-related AMH-derived DMRs are in genes known to associate with the voice. In archaic-derived DMRs and in
simulated DMRs, voice-associated genes do not show higher ranking compared to the rest of the DMGs. t-test P-values are shown for each group. b The
fraction of differentially methylated CpGs along the five chromosomes containing ACAN, SOX9, COL2A1, XYLT1, and NFIX. In each of these chromosomes,

















































































































































































































































































































Fig. 4 Hypermethylation of SOX9, ACAN, and COL2A1 in AMHs. a Methylation levels in the AMH-derived DMRs in SOX9, ACAN, and COL2A1. AMH
samples are marked with red lines, archaic human samples are marked with blue lines and chimpanzee samples are marked with gray lines. The distribution
of methylation across 52 AMH samples (450K methylation arrays) is presented in red. b SOX9 and its upstream regulatory elements. AMH-derived DMRs
are marked with red rectangles. Previously identified putative enhancers are marked with circles: human craniofacial (orange), human craniofacial,
chimpanzee-biased (blue), human skeletal (yellow), human non-skeletal (dark gray), and mouse (light gray). Numbers above skeletal enhancers show the
difference in mean bone methylation between AMHs and archaic humans (top) and between AMHs and chimpanzee (bottom). Across almost all SOX9
enhancers, AMHs are hypermethylated compared to archaic humans and the chimpanzee.
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because phonetic range is determined by the different config-
urations that the vocal tract can produce. The roles of divergent
anatomy vs. cognition in our speech skills are still debated45,46,
and some propose that even with a human brain, other apes could
not reach the human level of articulation and phonetic range44,47.
Regardless of its potential role in speech, the process of laryngeal
descent is developmentally and evolutionarily associated with
facial retraction48,49. In this regard, the observation that the top
five skeletal DMRs are found in genes that are associated with
both facial protrusion and the anatomy of the larynx suggests that
these two processes might have been genetically linked, though
the interaction between the two is still to be determined, as their
exact developmental pathways are beyond the scope of the
current study. Thus, it is still to be determined how the positional
and structural changes to the larynx emerged and what was the
role of the reported methylation changes in this process. For an
in-depth review of the anatomy of vocalization and speech, see
refs. 44,46.
A longstanding question is whether Neanderthals and AMHs
share similar vocal tract anatomy50,51. Attempts to answer this
question based on morphological differences have proven hard, as
the larynx is mostly composed of soft tissues (e.g., cartilage),
which do not survive long after death. The only remnant from the
Neanderthal laryngeal region is the hyoid bone, which is detached
from the rest of the skull51. Based on this single bone, or on
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P = 3.1 × 10–17P = 7.2 × 10–4P = 3.0 × 10–5P = 2.8 × 10–6
XYLT1
P = 6.1 × 10–22
Fig. 5 DNA methylation and expression pattern of NFIX in modern and archaic humans. a Methylation levels along NFIX, color-coded from green
(unmethylated) to red (methylated). Methylation levels around the two AMH-derived DMRs (#24 and #167) are shown in the zoomed-in panels. These
two DMRs represent the regions where the most significant methylation changes are observed, but hypermethylation of NFIX in AMHs can be seen
throughout the entire gene body. Chimpanzee and present-day samples were smoothed using the same sliding window as in ancient samples to allow
easier comparison. The inferred schematic regulatory evolution of NFIX is shown using a phylogenetic tree to the left of the top panel. Star marks the shift
in methylation from unmethylated (green) to methylated (red). b Methylation levels in DMRs #167 and #24 vs. expression levels of NFIX across 22 AMH
tissues (gray). In both DMRs, higher methylation is significantly associated with lower expression of NFIX. Ust’-Ishim, Bone1 and Bone2 methylation levels
(red) are plotted against mean NFIX expression across 13 osteoblast lines. Neanderthal and Denisovan methylation levels (green) are plotted against their
predicted expression levels, based on the extrapolated regression line (dashed). Standard errors are marked with dotted lines. The expression levels of NFIX
in Neanderthal and Denisovan shown in these graphs are extrapolated (green dots). c Box plots of expression levels of NFIX, COL2A1, ACAN, SOX9, and
XYLT1 in 89 AMH samples (red) and four mouse samples (green) from appendicular bones (limbs and pelvis). Central line shows mean, box borders show
25th and 75th percentiles, whiskers extend to the most extreme data points not considered outliers, crosses show outliers. Expression levels were
converted to percentiles based on the level of gene expression compared to the rest of the genome in each sample. t-test P-values are shown for
each gene.
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is difficult to characterize the full anatomy of the Neanderthal
vocal apparatus, and opinions remain split as to whether it was
similar to that of AMHs50,51.
Most skeletal disease phenotypes that result from NFIX dys-
function are craniofacial, as NFIX influences the balance between
lower and upper projection of the face52. In addition, mutations
in NFIX were shown to impair speech capabilities42,53. The exact
mechanism is still unknown, but is thought to occur partly
through skeletal alterations to the larynx42. To investigate if
































































P = 6.0 × 10–4
Larynx Hyoid Epiglottis Tongue
a
Fig. 6 NFIX down-regulation is associated with modern human-derived traits. a Vocal anatomy of chimpanzee and AMH. The vocal tract is the cavity
from the lips to the larynx (marked by dashed lines). In AMHs, the flattening of the face together with the descent of the larynx led to approximately 1:1
proportions of the horizontal and vertical portions of the vocal tract. b Craniofacial features of the Neanderthal, healthy AMH, and AMH with Marshall-
Smith or Malan syndromes. Each box shows a phenotype that occurs in the Marshall-Smith/Malan syndromes (i.e., when NFIX is partially or completely
inactive). The righthand side of each box shows the observed phenotypes of individuals with the syndromes (left), healthy AMHs (middle) and
Neanderthals (right). In most phenotypes, the observed phenotypes match the expected phenotypes based on NFIX expression. Binomial test P-value
is shown.
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in the AMH face and larynx, we examined its clinical skeletal
phenotypes. Mutations in NFIX were shown to cause the
Marshall–Smith and Malan syndromes, whose phenotypes
include various skeletal alterations such as hypoplasia of the
midface, retracted lower jaw, and depressed nasal bridge52. In
many patients, the phenotypic alterations are driven by hetero-
zygous loss-of-function mutations that cause haploinsufficiency.
This shows that reduced activity of NFIX, even if partial, results in
skeletal alterations52. Because NFIX is inferred to have been
downregulated in AMHs compared to archaic humans, we
hypothesized that similar phenotypes to the ones that are driven
by NFIX loss-of-function may also exist between modern and
archaic humans. For example, because reduced activity of NFIX
results in a more retracted face, we hypothesized that AMHs
would present a more retracted face compared to archaic humans.
A similar relationship between facial features and gene dosage has
been recently shown in the 16p11.2 locus in humans54. We
therefore examined the phenotypes of the Marshall–Smith and
Malan syndromes and found that not only do most of these
phenotypes exist between Neanderthals and modern humans, but
their direction matches the direction expected from NFIX
downregulation along the AMH lineage (18 out of the 22
Marshall–Smith phenotypes, and 8 out of the 9 Malan pheno-
types, P= 6.0 × 10−4, binomial test). In other words, from the
Neanderthal, where NFIX activity is expected to be highest,
through healthy AMHs, to individuals with NFIX haploinsuffi-
ciency, phenotypic manifestation matches the level of NFIX
activity (Fig. 6b and Supplementary Data 8).
Notably, many cases of laryngeal malformations in the
Marshall–Smith syndrome have been reported. Some of the
patients exhibit positional changes to the larynx, changes in its
width, and, more rarely, structural alterations to the arytenoid
cartilage—the anchor point of the vocal folds, which controls
their movement55. In fact, these laryngeal and facial changes are
thought to underlie some of the limited speech capabilities
observed in various patients42. This raises the possibility that
NFIX downregulation in AMHs might be associated with changes
in the larynx too.
SOX9, ACAN, COL2A1, XYLT1, and NFIX are active in early
stages of osteochondrogenesis, making the observation of differ-
ential methylation in mature bones puzzling at first glance. This
could potentially be explained by two factors: (i) The methylome
stabilizes as development progresses and remains largely
unchanged from late development through adulthood. Thus,
adult methylation states often reflect earlier development, and
DMRs in adult stages often reflect DMRs in earlier activity
levels3,17,56. Therefore, these DMRs might reflect early methyla-
tion changes in mesenchymal progenitors that are carried over to
later stages of osteogenesis. Indeed, the methylation patterns of
NFIX, SOX9, ACAN, and COL2A1 were shown to be established
in early stages of human development and remain stable
throughout differentiation from mesenchymal stem cells to
mature osteocytes57. It is further supported by the observation
that osteoblasts and chondrocytes show almost identical methy-
lation levels in these DMRs, and are all as hypermethylated as the
adult bone methylation levels we report58. We have reconfirmed
this result by measuring methylation in these DMGs in primary
human chondrocytes. Finally, we show that the upstream
mesenchymal enhancer of SOX9 (ref. 23) is differentially methy-
lated in AMHs (Fig. 4b). (ii) Although expression levels of SOX9,
ACAN, and COL2A1 gradually decrease with skeletal maturation,
these genes were shown to remain active in later developmental
stages in the larynx, vertebrae, limbs, and jaws, including in their
osteoblasts21,59. Interestingly, these are also the organs that are
most affected by mutations in these genes, implying that their late
stages of activity might still play important roles in morphological
patterning20,39–41. It was also shown that facial growth patterns,
which shape facial prognathism, differ between archaic and
modern humans not only during early development, but also as
late as adolescence60. Moreover, the main differences between
human and chimpanzee vocal tracts are established during post-
infant years61.
Although the DMRs we report most likely exist throughout the
skeleton, including the larynx, the evidence we present for the
cranium is more direct, as the patterns are observed in modern
human and chimpanzee crania. Importantly, it has been sug-
gested that the 1:1 vocal conformation could have been entirely
driven by cranial, rather than laryngeal, alterations49. Once
archaic human cranial samples are sequenced, these observations
could be more directly tested.
The results we presented open a window to study the evolution
of the human vocal tract and face from genetic and epigenetic
perspectives. Our data suggest shared genetic mechanisms that
shaped these anatomical regions and point to evolutionary events
that separate AMHs from the Neanderthal and Denisovan. The
mechanisms leading to such extensive regulatory shifts, as well as
if and to what extent these evolutionary changes affected voca-
lization and speech capabilities are still to be determined.
Methods
Skeletal methylation maps. Previously, our ability to identify differentially
methylated regions (DMRs) that discriminate between human groups was confined
by three main factors: (i) We had a single DNA methylation map from a present-
day human bone, which was produced using a reduced representation bisulfite
sequencing (RRBS) protocol, which provides information for only ~10% of CpG
positions in the genome. Moreover, the fact that the archaic and present-day
methylomes were produced using different technologies—computational recon-
struction versus RRBS—potentially introduces a bias. (ii) The analyses included
only one bone methylation map from each of the human groups, which limited our
ability to identify fixed differences between the groups. Although dozens of maps
from additional tissues in present-day humans were included in the analyses, this
narrowed the DMRs to represent only human-specific changes that are invariable
between tissues. (iii) The work did not include a great ape outgroup. Thus, when a
AMH-specific change was identified, it was impossible to determine whether it
happened on the AMH lineage, or in the ancestor of Neanderthals and
Denisovans4.
To overcome these obstacles, a major goal of the current study was to
significantly extend the span of our skeletal methylome collection, covering as
many individuals, sexes, and bone types as we could. This included the generation
of many samples, including the high-coverage sequencing of additional ancient
genomes, as listed below.
Present-day human bone DNA methylation maps. We generated full DNA
methylation maps from two femur head bones from present-day humans using
WGBS. Femora were chosen because of their abundance in present-day human
samples, as well as in ancient DNA samples5,6,62. In addition, we collected 53
publicly available partial skeletal methylation maps.
Trabecular bone tissue from femur heads were taken from two patients with
osteoarthritis during a total hip replacement surgery, and after filling in a consent
form as per Helsinki approval #0178-13-HMO. Importantly, the effects of
osteoarthritis processes on trabecular bone are much less substantial than those on
the synovium, cartilage, and subchondral bone. Bone1 was a left head of femur
taken on August 11, 2014 from a 66 years old female and Bone 2 was a right head
of femur taken on September 2, 2014 from a 63-years-old female.
DNA was extracted from bones using QIAamp® DNA Investigator kit (56504,
Qiagen). Bones were cut to thin slices (0.2–0.5 mm) and then thoroughly washed
(X5) with PBS, to clean samples from blood. Bones were crushed with mortar and
pestle in liquid nitrogen, and 100 mg bone powder was taken to extract DNA
according to the protocol Isolation of Total DNA from Bones and Teeth of the
DNA Investigator kit.
We followed the protocol described in ref. 63 to carry out whole-genome
bisulfite sequencing at the Center Nacional d’Anàlisi Genòmica (CNAG). In short,
DNA libraries were built with the Illumina TruSeq Sample Preparation kit. Bisulfite
treatment was applied in two rounds using the EpiTect Bisulfite kit (QIAGEN) and
paired-end sequencing was performed on an Illumina Hi-Seq 2000 instrument.
Reads were aligned using the GEM mapper64, with the reads fully converted in
silico. To this end, we generated two versions of each of the reference genomes—
human (GRCh37) and viral: in the first version, C’s were replaced with T’s, and in
the second version, G’s were replaced with A’s. Although methylation state should
not depend on read position, positional biases have been previously reported65. We
observed that the first few bases from each read showed a slightly higher
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probability of being called as methylated, and we thus trimmed the first ten bases
from each read (M-bias filtering).. Heterozygous positions, positions with a
genotype error probability greater than 0.01, and positions with a read depth
greater than 250 were filtered out. Only cytosines with six or more reads
informative for methylation status were considered. On average, half of the reads
from either strand will be informative for methylation status at a given position, so
minimum coverage is typically greater than 12. Methylated and unmethylated
cytosine conversion rates were determined from spiked-in bacteriophage DNA
(fully methylated phage T7 and unmethylated phage lambda). Five samples were
excluded based on conversion rates <0.997, supported by visual inspection of CG
and non-CG methylation plots. The over-conversion rates for all samples based on
methylated phage T7 DNA were ~5%.
Sequence quality was evaluated using FastQC software v0.11.2.
TRIMMOMATIC v.0–32 was used to filter low quality bases with the following
parameters: -phred33 LEADING:30 TRAILING:30 MAXINFO:70:0.9 MINLEN:70.
Paired-end sequencing reads were mapped to bisulfite converted human (hg19)
reference genome using Bismark v0.14.3 and bowtie2 v2.2.4 not allowing multiple
alignments and using the following parameters: –bowtie2 –non_bs_mm –old_flag
-p 4. Potential PCR duplicates were removed using Bismark’s
deduplicate_bismark_alignment_output.pl Perl program. Bismark’s
bismark_methylation_extractor script was used to produce methylation calls with
the following parameters: -p –no_overlap –comprehensive –merge_non_CpG –
no_header –bedGraph –multicore 2 –cytosine_report. Examination of the M-bias
plots led us to ignore the first 5 bp of both reads in human samples (Supplementary
Fig. 1). Custom scripts were used to summarize methylation levels at CpG sites
based on the frequencies of methylated and unmethylated mapped reads on both
strands. Methylation data were deposited in NCBI’s Gene Expression Omnibus and
are accessible through GEO accession number GSE96833.
Partial skeletal and full non-skeletal DNA methylation maps. Osteoblast RRBS
map, extracted from the femur, tibia, and rib bones of a 6-year-old female (NHOst-
Osteoblasts by Lonza Pharma, product code: CC-2538, lot number: 6F4124), was
downloaded from GEO accession number GSE27584. Forty-eight 450K methyla-
tion array maps, extracted from the femora of adult males and females with
osteoarthritis or osteoporosis, were downloaded from GEO accession number
GSE64490. Four 450K methylation array maps, extracted from unspecified bones of
adult males and females were downloaded from GEO accession number GSE50192.
Chimpanzee and human WGBS blood methylation maps were downloaded from
NCBI SRA accession number SRP059313. Chimpanzee and human WGBS brain
maps were downloaded from GEO accession number GSE37202.
Bisulfite-PCR of human bone. A skull of an adult male from India was obtained
from the teaching anatomy collection of the Department of Anatomy and
Anthropology at the Sackler Faculty of Medicine, Tel Aviv University, Israel
(Human 1). Additional two skull specimens (Human 2 and 3) were obtained
directly from the operating room of the Department of Neurosurgery, Shaare
Zedek Medical Center, Jerusalem, Israel and transferred on dry ice for further
analysis. All study participants provided informed consent according to an insti-
tutional review board—approved protocol (SZMC 0048-18).
Human 1: Standard precautions to avoid contamination were taken, including
wearing disposable coats, masks, hair covers and double gloves. All following steps
were performed in a UV cabinet dedicated for the preparation of ancient bone
samples and located in a physically separated ancient DNA laboratory at the
Faculty of Dental Medicine. The skull was cleaned with an excess of 10% bleach
(equal to 0.6% Sodium hypochlorite) and then subjected to UV radiation for
30 min The cortical layer on the temporal surface (facies temporalis) of the
zygomatic bone (ZB) was removed by low-speed drilling using a Wolf Multitool
Combitool Rotary Multi Purpose Tool equipped with a sterile dental burr. Another
sterile burr was used to obtain powder of the subcortical trabecular bone within the
body of the zygoma. The powder was collected onto a 10 × 10 cm aluminum foil
sheet pretreated with a 10% bleach solution and then transferred into a sterile
1.5 ml Eppendorf tube for subsequent DNA extraction. Altogether, three samples
were obtained: ZB-3 from the right zygoma weighing 20.3 mg, and ZB-3/1 and ZB-
3/2 from the left zygoma weighing 29.5 mg and 30.3 mg, respectively. Bone DNA
was purified from the three bone powder samples using QIAamp DNA Investigator
Kit (QIAgen, 56504) according to manufacturer’s instructions.
Human 2 and 3: DNA was extracted from bones using QIAamp® DNA
Investigator kit (56504, Qiagen). Bones were thoroughly washed (X5) with PBS, to
clean samples from blood. Bones were crushed with mortar and pestle in liquid
nitrogen, and 100 mg bone powder was taken to extract DNA according to the
protocol Isolation of Total DNA from Bones and Teeth of the DNA
Investigator kit.
Genomic DNA was bisulfite converted with the EZ DNAMethylation Lightning
Kit (Zymo Research, D5030) according to the manufacturer’s instructions.
Specifically, each bone sample was bisulfite converted using 500 ng as genomic
DNA input for the conversion.
Bisulfite treated DNA were amplified with the FastStart High Fidelity PCR
System (Sigma, 03553400001) using the primers listed in Supplementary Table 1.
PCR conditions were performed according to manufacturer’s instructions and PCR
products were visualized on a 1.5% agarose gel. Prior to cloning, PCR products
were purified with Gel/PCR DNA Mini Kit (RBC, YDF100) and quantified with a
NanoDrop 2000 spectrophotometer.
CloneJET PCR Cloning Kit (Thermo Scientific, K1231) was used to clone the
purified PCR products into a pJET1.2/blunt Cloning Vector following the Blunt-
End Cloning Protocol described in the manufacturer’s instructions. Five microliter
of each cloning reaction product were used for transformation of DH5α Competent
Cells (Invitrogen, 18265017). Colonies were grown overnight on LB plates
containing 100 μg/ml ampicillin. Positive transformants were picked and grown
overnight in liquid LB medium containing 100 μg/ml ampicillin. Subsequently,
plasmid minipreps were purified with a RBC Miniprep Kit (YPD100) according to
manufacturer’s instructions. Purified plasmids were quantified with a NanoDrop
2000 spectrophotometer and sequenced on an Applied Biosystems 3730xl Genetic
Analyzer (Supplementary Fig. 5a, b).
Human primary chondrocyte validation. Primary chondrocyte cultures were
obtained from osteoarthritis (OA) donors in accordance with Hadassah Medical
Center Institutional Review Board approval and in accordance with the Helsinki
Declaration of ethical principles for medical research involving human subjects.
End-stage OA patients, with a Kellgren and Lawrence OA severity score of 3–4
were recruited following receipt of a formal written informed consent (n= 8; 75%
female, mean age 73 ± 7.2 years; mean body mass index 30.1 ± 5.4 kg/m2). Hyaline
articular cartilage was dissected and human chondrocytes isolated using 3 mg/ml
Collagenase Type II (Worthington Cat # LS004177) in DMEM medium (Sigma-
Aldrich, St Louis, MI) containing 10% FCS and 1% penicillin-streptomycin (Beit-
Haemek Kibutz, Israel), 37 °C, 24 h incubation. Isolated cells were filtered through
a nylon cell strainer (40 mm diameter), washed three times with PBS and plated at
1.5 million cells per 14 cm2 tissue culture dish (passage 0, passage 2). Cells were
cultured in standard incubation conditions (37 °C, 5% CO2) until confluence.
Chondrocyte DNA purification was performed using GenElute™ Mammalian
Genomic DNA Miniprep Kit (Sigma, G1N350).
Chimpanzee bone DNA methylation maps. Overall, we produced six methylation
maps from bones of six common chimpanzee (Pan troglodytes) individuals. They
include one WGBS of a wild chimpanzee, one RRBS of an infant chimpanzee, and
four 850K methylation arrays of captive chimpanzees.
Chimpanzee tissue samples included in this study were opportunistically
collected at routine necropsy of these animals. No animals were sacrificed for this
study, and no living animals were used in this study.
WGBS of a chimpanzee bone. We used a rib bone of a 47-year-old
female Chimpanzee provided from the Biobank of the Biomedical Primate
Research Center (BPRC), The Netherlands. The postmortem interval was
approximately 10–12 h. The bone was collected during the necropsy procedure and
immediately frozen and stored at –80 °C.
DNA was extracted in a dedicated ancient DNA laboratory at the Institute of
Evolutionary Biology in Barcelona, where no previous work on great apes has ever
been conducted. Standard precautions to avoid and monitor exogenous
contamination such as frequent cleaning of bench surfaces with bleach, use of
sterile coveralls, UV irradiation and blank controls were taken during the process.
Two hundred milligram of bone powder were obtained by drilling and the sample
was extracted following the Dabney et al.66 method. A final 25 µl of extract volume
was used for genome sequencing.
Analysis was performed similarly to Bone1 and Bone2, with the exception that
the BSreads were mapped to bisulfite converted chimpanzee (panTro4) reference
genome, and we ignored the first 5bp of read1 and the first 44 bp of read2 in the
chimpanzee sample (Supplementary Fig. 1). Methylation data were deposited in
NCBI’s Gene Expression Omnibus and are accessible through GEO accession
number GSE96833.
RRBS of a chimpanzee bone. We used two unidentified long bone fragments that
belonged to a newborn wild chimpanzee infant who died during a documented
infanticide event at Gombe National Park on 9 March 2012. The infant was known
to be the offspring of a chimpanzee called Eliza and was partially eaten by an adult
female and her family. The sample was collected from the ground about 48 h after
the infant's death and stored in RNAlater solution until arrival at Arizona State
University (ASU). At ASU the sample was stored at 4 °C until extraction.
Sampling and DNA extractions were conducted at the ASU Ancient DNA
Laboratory, a Class 10,000 clean-room facility in a separate building from the
Molecular Anthropology Laboratory. Precautions taken to avoid contamination
included bleach decontamination and UV irradiation of tools and work area before
and between uses, and use of full body coverings for all researchers. The bone
samples were pulverized together in December 2012 using a SPEX CertiPrep
Freezer Mill. Three DNA extractions were conducted using 50–100 mg of bone
powder (Supplementary Table 2) and following the extraction protocol by Rohland
and Hofreiter67. Two extraction blank controls were included to monitor
contamination of the extraction process. One microliter each of the sample extract
and the blank control were used for fluorometric quantification with the Qubit 2.0
Broad Range assay. All extracts were combined for a total volume of 345 µl and
approximately 0.652 µg of total DNA.
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RRBS libraries were generated according to Boyle et al.68. 100–200 ng genomic
DNA was digested with MspI. Subsequently, the digested DNA fragments were
end-repaired and adenylated in the same reaction. After ligation with methylated
adapters, samples with different adapters were pooled together and were subjected
to bisulfite conversion using the EpiTect Bisulfite kit (QIAGen) per the
manufacturer’s recommendations with the following modification: after first
bisulfite conversion, the converted DNA was treated with sodium bisulfite again to
guarantee that conversion rates were no less than 99%. Two third of bisulfite
converted DNA was PCR amplified and final RRBS libraries were sequenced in an
Illumina HiSeq 2000 sequencer (Supplementary Data 1). Methylation data were
deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO
accession number GSE96833.
850K DNA methylation arrays. Four chimpanzee cadavers from captive colonies
at the Southwest National Primate Research Center in Texas were used. Femora
were opportunistically collected at routine necropsy of these animals and stored in
−20 °C freezers at the Texas Biomedical Research Institute after dissection. These
preparation and storage conditions ensured the preservation of skeletal DNA
methylation patterns.
Samples were then transported to ASU and DNA was extracted from the
femoral trabecular bone using a phenol-chloroform protocol optimized for skeletal
tissues69. From the distal femoral condyles, trabecular bone was collected using
coring devices and pulverized into bone dust using a SPEX SamplePrep Freezer/
Mill. Specifically, bone cores were obtained from a transverse plane through the
center of the medial condyle on the right distal femur, such that the articular
surface remained preserved. Cortical bone was removed from these cores using a
Dremel (Supplementary Table 3). Tissue collections were performed at the Texas
Biomedical Research Institute, and DNA extractions were conducted at the ASU
Molecular Anthropology Laboratory.
Genome-wide DNA methylation was assessed using Illumina Infinium
MethylationEPIC microarrays. These arrays analyze the methylation status of over
850,000 sites throughout the genome, covering over 90% of the sites on the
Infinium HumanMethylation450 BeadChip as well as an additional 350,000 sites
within enhancer regions. For each sample, 400 ng of genomic DNA was bisulfite
converted using the EZ DNA MethylationTM Gold Kit according to the
manufacturer’s instructions (Zymo Research), with modifications described in the
Infinium Methylation Assay Protocol. These protocols were conducted at the ASU
Molecular Anthropology Laboratory. Following manufacturer guidelines
(Illumina), this processed DNA was then whole-genome amplified, enzymatically
fragmented, hybridized to the arrays, and imaged using the Illumina iScan system.
These protocols were conducted at the Texas Biomedical Research Institute. These
array data have been deposited in NCBI’s Gene Expression Omnibus and are
accessible through GEO Series accession number GSE94677.
Raw fluorescent data were normalized to account for the noise inherent within
and between the arrays themselves. Specifically, we performed a normal-
exponential out-of-band (Noob) background correction method with dye-bias
normalization to adjust for background fluorescence and dye-based biases and
followed this with a between-array normalization method (functional
normalization) which removes unwanted variation by regressing out variability
explained by the control probes present on the array as implemented in the minfi
package in R which is part of the Bioconductor project. This method has been
found to outperform other existing approaches for studies that compare conditions
with known large-scale differences70, such as those assessed in this study.
After normalization, methylation values (β values) for each site were calculated
as the ratio of methylated probe signal intensity to the sum of both methylated and
unmethylated probe signal intensities. These β values range from 0 to 1 and
represent the average methylation levels at each site across the entire population of
cells from which DNA was extracted (0= completely unmethylated sites, 1= fully
methylated sites).
β ¼ Methylated signalðMethylated signal þ unmethylated signalÞ
Every β value in the Infinium platform is accompanied by a detection P-value,
and those with failed detection levels (P-value > 0.05) in greater than 10% of
samples were removed from downstream analyses.
The probes on the arrays were designed to specifically hybridize with human
DNA, so our use of chimpanzee DNA required that probes non-specific to the
chimpanzee genome, which could produce biased methylation measurements, be
computationally filtered out and excluded from downstream analyses. This was
accomplished using methods modified from Hernando-Herraez et al.71. Briefly, we
used blastn to map the 866,837 50 bp probes onto the chimpanzee genome
(Assembly: Pan_tro_3.0, Accession: GCF_000001515.7) using an e-value threshold
of e−10. We only retained probes that successfully mapped to the genome, had only
1 unique BLAST hit, targeted CpG sites, had 0 mismatches in 5 bp closest to and
including the CpG site, and had 0–2 mismatches in 45 bp not including the CpG
site. This filtering retained 622,819 probes.
Additionally, β values associated with cross-reactive probes, probes containing
SNPs at the CpG site (either human or chimpanzee), probes detecting SNP
information, probes detecting methylation at non-CpG sites, and probes targeting
sites within the sex chromosomes were removed using the minfi package in R. This
filtering retained a final set of 576,505 probes.
Bisulfite-PCR of chimpanzee cranial bones. Postmortem frontal skull bones from
two different chimpanzees (chimpanzee 1 and chimpanzee 2) were provided by the
Biomedical Primate Research Center (BPRC, The Netherlands). Bones were
opportunistically collected during routine necropsy of these animals and stored at
−80 °C. Chimpanzee 3 and chimpanzee 4 samples were obtained from the chim-
panzee cranial collection in the Department of Paleoanthropology in the Senck-
enberg Research Institute Frankfurt (DPSF) and Natural History Museum
Frankfurt. These two chimpanzee specimens are owned by the Justus Liebig
University Gießen.
Chimpanzee 1 and chimpanzee 2: For each sample, bone powder was obtained
by crushing the bones with mortar and pestle. Approximately 100 mg bone powder
were used to extract DNA using the QIAamp DNA Investigator Kit (Qiagen)
following manufacturer’s instructions.
Chimpanzee 3 and chimpanzee 4: Cochlear bone powder was obtained by
accessing the petrous bone from the cranial base72. DNA was extracted from about
50 mg of powder according to the protocol described by Dabney et al.66, but
adapted for the use of High Pure Nucleic Acid Large Volume columns (Roche)
instead of the Zymo-Spin V column (Zymo Research) MinElute silica spin column
(Qiagen) combination.
Genomic DNA was bisulfite converted with the EZ DNA Methylation—
Lightning Kit (Zymo Research, D5030) according to the manufacturer’s
instructions. Specifically, each bone sample was bisulfite converted two times in
parallel using 500ng as genomic DNA input for the conversion.
Three microliter of bisulfite treated DNA were amplified with the FastStart
High Fidelity PCR System (Sigma, 03553400001) using the primers listed in
Supplementary Table 1. PCR conditions were performed according to
manufacturer’s instructions and PCR products were visualized on a 1.5% agarose
gel. Prior to cloning, PCR products were purified with homemade SPRI beads
(chimpanzee 1 and 2) and Gel/PCR DNA Mini Kit (RBC, YDF100, chimpanzee 3
and 4), and quantified with a NanoDrop 2000 spectrophotometer.
CloneJET PCR Cloning Kit (Thermo Scientific, K1231) was used to clone the
purified PCR products into a pJET1.2/blunt Cloning Vector following the Blunt-
End Cloning Protocol described in the manufacturer’s instructions. Three
microliter (chimpanzee 1 and 2) and 3 µl (chimpanzee 3 and 4) of each cloning
reaction product were used for transformation of DH5α Competent Cells
(Invitrogen, 18265017). Colonies were grown overnight on LB plates containing
100 μg/ml ampicillin. Positive transformants were picked and grown overnight in
liquid LB medium containing 100 μg/ml ampicillin. Subsequently, plasmid
minipreps were purified with a QIAprep Miniprep Kit (Qiagen, chimpanzee 1 and
2), and RBC Miniprep Kit (YPD100, chimpanzee 3 and 4) according to
manufacturer’s instructions. Purified plasmids were quantified with a NanoDrop
2000 spectrophotometer and sequenced on an Applied Biosystems 3730xl Genetic
Analyzer (Supplementary Fig. 5a, b).
Reconstructing ancient DNA methylation maps. In a dedicated clean room at
Harvard Medical School, powder was extracted from the root of a lower third
molar of the Mesolithic La Braña 1 individual (5983–5747 calBCE (6980 ± 50 BP,
Beta-226472)), from which a non-UDG-treated library was previously sequenced
to 3.5× coverage8. Two UDG-treated libraries from the same individual were later
generated and enriched for approximately 1.2 million single targeted polymorph-
isms and sequenced to an average of 19.5× coverage at these position9. In this
study, we carried out shotgun sequencing of one of the same UDG-treated libraries
from this individual on a NextSeq500 instrument using 2 × 76 bp paired end
sequences. Following the mapping protocol described previously9, we trimmed
adapter sequences, only processed read pairs whose ends overlapped by at least
15 bp (allowing for one mismatch) so that we could confidently merge them, and
then mapped to the human reference sequence hg19 using the command samse in
BWA (v0.6.1). We removed duplicated sequences by identifying sequences with the
same start and stop position and orientation in the alignment, and picking the
highest quality one. After restricting to sequences with a map quality of MAPQ ≥
10, and sites with a minimum sequencing quality (≥20), we had an average cov-
erage measured at the same set of approximately 1.2 million single nucleotide
polymorphism targets of 23.0×. This data is available under GEO accession
number: GSE96833, with raw reads deposited under SRA accession number:
SRX3194436.
In a dedicated clean room at the University College Dublin, powder was
extracted from the cochlear portion of the petrous bone of individual I1583
(archeological ID L14-200) from the site of Barcın Höyük in the Yenişehir Plain of
the Marmara Region of Northwest Turkey. The Neolithic individual came from a
community that practiced farming, and was anthropologically determined to be
a male aged 6–10 years at the time of death (the sex was confirmed genetically).
The direct radiocarbon date was 6426-6236 calBCE (7460 ± 50 BP, Poz-82231). In a
dedicated clean room at Harvard Medical School, a UDG-treated library was
prepared from this powder, which was previously enriched for about 1.2 million
SNP targets, sequenced to 13.5× average coverage, and published in ref. 9. We
shotgun sequenced the same library on nine lanes of a HiSeqX10 sequencing with
100bp paired reads. On data processing, we merged overlapping read pairs,
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trimmed Illumina sequencing adapters, and dropped read pairs that did not have
sample barcodes (up to one mismatch) or cannot be unambiguously merged. We
then aligned merged reads with BWA against human reference genome GRCh37
(hg19) plus decoy sequences, and combined all nine lanes of data and removed
duplicate molecules, achieving an average of 24.3× coverage evaluated on the 1.2
million targets. This data is available under GEO accession number: GSE96833,
with raw reads deposited under SRA accession number: SRX3194436.
The reconstruction procedure. Reconstruction of DNA methylation maps was
performed on the genomes of the following individuals: Ust'-Ishim6, Loschbour7,
Stuttgart7, La Braña 1, I1583, and the Vindija Neanderthal5, as well as on the
previously published Altai Neanderthal and the Denisovan (Supplementary
Data 1). The Vindija Neanderthal reads were downloaded from the Max Planck
Institute for Evolutionary Anthropology website: http://cdna.eva.mpg.de/
neandertal/Vindija/bam/. Only the UDG-treated portion of the genome (B8744)
was used. Additional UDG-treated ancient human full genomes have been pub-
lished to date; however, these were sequenced to a relatively low coverage (<5×),
and thus, only crude methylation maps could be reconstructed from them. C→T
ratio was computed for every CpG position along the hg19 (GRCh37) human
genome assembly, for each of the samples4.
In order to exclude from the analyses positions that potentially represent pre-
mortem C→T mutations rather than post-mortem deamination, the following
filters were applied: (i) Positions where the sum of A and G reads was greater than
the sum of C and T reads were excluded. (ii) For genomes that were produced
using single-stranded libraries (i.e., Ust'-Ishim, Altai Neanderthal, Denisovan,
Vindija Neanderthal and ~1/3 of the Loschbour library) positions, where the G→
A ratio on the opposite strand was greater than 1/(average single strand coverage)
were excluded. This fraction represents a threshold of one sequencing error allowed
per position. For Loschbour, this was performed only on the fraction of reads that
came from the single stranded library. (iii) For all genomes, positions with a C→ T
ratio >0.25 were discarded. For the Vindija Neanderthal, this threshold was raised
to 0.5, due to its relatively low coverage (~7×). (iv) Finally, a maximum coverage
threshold of 100 reads was used to filter out regions that are suspected to be PCR
duplicates.
In all genomes, excluding Vindija, a fixed sliding window of 25 CpGs was used
for smoothing of the C→ T ratio. This allowed for an unbiased scanning of
differentially methylated regions (DMRs) that is not affected by the size of the
window. Due to its relatively low coverage, we extended the sliding window used
on the Vindija genome to 50 CpGs. This extended window is not expected to
introduce a bias, as this genome was not used for DMR detection, but only for
subsequent filtering that was applied equally to all genomes (see later).
C→ T ratio was translated to methylation percentage using linear
transformation determined from two points: zero C→ T ratio was set to the value
0% methylation, and mean C → T ratio in completely methylated (100%
methylation) CpG positions in modern human bone reference (hereinafter μ100)
was set to the value 100% methylation. Positions where C→ T ratio > μ100 were set
to 100% methylation. For genomes that were extracted from bones, the modern
Bone 2 WGBS map, which is the one with the higher coverage between the two
WGBS modern bone maps, was used to determine μ100. For genomes that were
extracted from teeth, there was no available modern reference methylation map,
and therefore, we transformed the C → T ratio into methylation percentage based
on the assumption that the genome-wide mean methylation is similar to bone
tissue. Thus, the genome-wide mean C → T ratio represents 75% methylation,
which is the genome-wide mean of measured methylation in the Bone 2 reference
map. This was accomplished by setting μ100 to 1.33× mean genome-wide C →
T ratio.
DMR detection. The DMR detection algorithm is comprised of five main steps.
We hereby provide an overview of the algorithm followed by a detailed description
of each step. The overall goal of this pipeline is to detect differential methylation,
assign it to the lineage on which it arose and filter out within-lineage variation.
Step 1: Two-way comparisons. To avoid artifacts that could potentially be
introduced by comparing DNA methylation maps that were produced using
different technologies, our core analysis relied on the comparison of the three
reconstructed maps of the Altai Neanderthal, Denisovan, and Ust’-Ishim. Each of
the samples was compared to the other two in a pair-wise manner, as a raw C→ T
ratio map against a reconstructed methylation map, and vice versa. This reciprocal
comparison insured that the reconstruction process does not introduce biases to
one of the groups. The minimum methylation difference threshold was set to 50%,
spanning >50 CpGs.
Step 2: Three-way comparisons. This step classifies to which of the three
hominins the DMR should be attributed. This step is done by overlapping the three
lists of DMRs found in Step 1. For example, a DMR that is detected between the
Neanderthal and Ust’-Ishim and also between the Denisovan and Ust’-Ishim is
considered specific to Ust’-Ishim.
Step 3: FDR filtering. Various factors could introduce noise to the
reconstruction process, including the stochasticity of the deamination process, the
use of a sliding window, and variations in read depth within a sample. We ran
simulations that mimic the post-mortem degradation processes of ancient DNA,
then reconstructed methylation maps from the simulated deamination maps and
finally compared them to the original map and identified DMRs. Any differences in
methylation levels between the simulated map and the original reference map stem
from noise. Thus, running the same DMR-detection algorithm on the simulated
map vs. the reference map, enables an estimation of the false discovery rate. We set
the DMR-detection thresholds so that FDR < 0.05.
Step 4: Lineage assignment. The chimpanzee methylation maps were used to
polarize the DMRs. For each DMR, methylation levels in the chimpanzee were
compared to those of the three hominin groups. For example, if methylation levels
in the chimpanzee samples clustered with the archaic humans, the DMR was
assigned to the AMH lineage.
Step 5: Within-lineage variability filtering. To determine whether a DMR
represents an individual within a group, or is shared by the entire group, we used a
total of 67 AMH, archaic and chimpanzee methylation maps. We used a
conservative approach, where DMRs in which methylation levels in one group
overlap (even partially) the methylation levels in another group were discarded. As
59 out of the 67 maps belong to AMHs, our ability to filter out variation within this
group was better, resulting in fewer DMRs along this lineage. Several various
measures were used to ascertain that a DMR along a lineage does not represent a
sex-specific, bone-specific, age-specific, technology, or disease-specific DMR.
DMR-detection algorithm. We developed an algorithm specifically designed to
identify DMRs between a deamination map and a full methylome reference. Let i
enumerate the CpG positions in the genome. In the deamination map, let ti be the
number of T’s at the C position + the number of A’s in the opposite strand at the G
position, i.e., it counts the total number of T’s that appear in a position that is
originally C, in the context of a CpG dinucleotide. We similarly use ci to count the
total number of C’s that appear in a position that is originally C, in the context of a
CpG dinucleotide. The C→ T ratio is defined as ti/ni, where ni= ci+ ti. Let φi and
ψi (both between zero and one) be the methylation of this position in the reference
genome and in the reconstructed one, respectively. If we denote by π the deami-
nation rate, assumed to be constant throughout the genome, and if we assume that
deamination of C into T is a binomial process with probability of success πψi,
we get
ti  B ni; πψi
  ð1Þ
Our null hypothesis is that the ith CpG is not part of a DMR, namely that ψi=
φi. The alternative hypothesis states that this CpG is part of a DMR. The definition
of this statement is that |ψi − φi| ≥ Δ, where Δ is some pre-specified threshold. In
other words, under the alternative hypothesis we get that ψi ≥ φi+ Δ if the site has
low methylation in the reference genome, and ψi ≤ φi− Δ if it has high methylation
in the reference genome.
Per-site statistic. Let us start with the first option, testing whether ψi ≥ φi+ Δ
when φi is low. A log-likelihood-ratio statistic would be
‘þi ¼ ln
Pr tijni; π φi þ Δ
  
Pr tijni; πϕi
  ¼ ti ln 1þ Δφi
 









Similarly, we can test whether ψi ≤ φi− Δ when φi is high using the log-
likelihood-ratio statistic
‘i ¼ ln
Pr tijni; π φi  Δ
  
Pr tijni; πϕi
  ¼ ti ln 1 Δφi
 









We used the value Δ= 0.5 for all samples. The value of π, the deamination rate,
was estimated using the overall C→ T ratio in CpG positions whose methylation
level is 1 in the modern human Bone 2 WGBS methylation map, after exclusion of
putative pre-mortem substitutions, as described in the reconstruction procedure
section (Supplementary Data 1).
Detecting DMRs. The statistics ‘þi and ‘

i quantify how strongly the estimated
methylation in position i deviates from φi. Next, we use these values to identify
DMRs using the cumulative-sum procedure explained below. The process is
repeated twice: on the statistic ‘þi to identify DMRs where the sample has elevated
methylation with respect to the reference, and on the statistic ‘i to identify DMRs
where the sample has reduced methylation with respect to the reference.
For convenience, we explain the cumulative-sum procedure in the context of
‘þi , but an essentially identical procedure is used for ‘

i . We define a new vector Q
+
by the recursion
Qþ0 ¼ 0; Qþi ¼ maxðQþi1 þ ‘þi ; 0Þ:
Under the null hypothesis, ‘þi has a negative expectation which produces a
negative drift that keeps Q+ at zero, or close to zero, levels. Under the alternative
hypothesis the expectation is positive, hence the drift over a DMR is positive,
leading to an elevation in the values of Q+. Therefore, our next step is to find all
intervals [a, b] such that Qþa1 ¼ 0, Qþbþ1 ¼ 0, and Qþi > 0 for a ≤ i ≤ b. Let Qþm be
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the maximum value of Q+ in this interval, where m is the position of the
maximum. Then, the interval [a, m] would be called a putative DMR.
The statistics ‘þi and ‘

i are affected by the number of observed cytosine reads,
and thus have higher power to detect hypermethylation (i.e., larger number of
cytosine reads) vs. hypomethylation (Supplementary Fig. 3).
Filtering DMRs. Of course, Q+may increase locally due to randomness, and thus a
putative DMR may not reflect a true DMR. To filter out such intervals, we used two
strategies. First, we applied a set of filters to assure that the putative DMRs have
reasonable biological properties. Second, we cleaned the remaining putative DMRs
by applying a false discovery rate (FDR) procedure. In the first strategy, we applied
two filters: (i) Putative DMRs that harbor less than 50 CpG positions, thus are
shorter than twice the smoothing window size, were removed. (ii) To avoid
situations where two consecutive CpG sites whose genomic locations are remote
appear on the same DMR, we modify the vector Qþi as follows. Let di,j be the
distance along the genome (in nucleotides) between CpG sites i and j. Then, for
every site i such that di,i–1 > δ we set Q
þ
i ¼ 0. We used δ= 1000 nt for all samples.
To further remove putative DMRs that are unlikely to reflect true DMRs, we
eliminated all DMRs where Qþm<Q
þ
T . Here, Q
þ
m is the maximum value of Q
+ in the
interval as defined earlier, and QþT is a threshold determined using a false discovery
rate (FDR) procedure, see the Filtering out noise section below.
Testing the algorithm. To verify that the approach above results in a low number
of false positives, we applied the procedure to deamination maps, when compared
to themselves in the form of reconstructed methylomes. As expected, we obtained a
negligible number of DMRs, ranging between 0.4 and 1% of the number of DMRs
detected between the humans.
Two-way DMR detection. In order to avoid artifacts that could potentially be
introduced by comparing DNA methylation maps that were produced using dif-
ferent technologies, our core analysis relied on the comparison of the three
reconstructed maps of the Altai Neanderthal, Denisovan, and Ust’-Ishim. These are
all high-resolution maps that were derived from genomes sequenced to high
coverage (Supplementary Data 1). In particular, the Ust’-Ishim methylome is of
exceptional quality due to its high coverage and deamination rate (Supplementary
Data 1). Also, going through the same post-mortem degradation processes, the
Ust'-Ishim cellular composition is likely to be similar to that of the Neanderthal
and Denisovan.
In order for a deamination map to serve as a reference in the comparison, we
have transformed its C→ T ratio values into methylation values (see The
reconstruction procedure section above). To remove potential bias that could be
introduced through the comparison of a reconstructed methylation map to a
deamination map, we ran each two-way comparison twice: once with the
methylation map of sample 1 against the deamination map of sample 2, and once
with the deamination map of sample 1 against the methylation map of sample 2
(Supplementary Fig. 3). Therefore, the comparison of three genomes required a
total of six two-way comparisons: Ust’-Ishim versus an Altai Neanderthal
reference, Ust’-Ishim versus a Denisovan reference, Altai Neanderthal versus an
Ust’-Ishim reference, Altai Neanderthal versus a Denisovan reference, Denisovan
versus Ust’-Ishim reference, and Denisovan versus Altai Neanderthal reference.
Because the DNA of these three individuals was extracted from both sexes, the
DMR-detection algorithm was only applied to autosomes.
Three-way DMR detection. In order to identify DMRs where one group of
humans (hereinafter, hominin 1) differs from the other two human groups
(hereinafter, hominin 2, and hominin 3), we set out to find those DMRs that were
detected both between hominin 1 and 2, and between hominin 1 and 3. To this
end, we compare the two lists (hominin 1 vs. hominin 2 and hominin 1 vs.
hominin 3) and look for overlapping DMRs4. An overlapping DMR exists when a
DMR from one list partially (or fully) overlaps a DMR from the second list. Only
the overlapping portion of the two DMRs from the two-lists was taken.
Filtering out noise. There are different factors that potentially introduce noise into
the reconstruction process. These include the stochasticity of the deamination
process, the use of a sliding window to smooth the C→ T signal, and variations in
read depth. In order to account for these factors and estimate noise levels, we ran
simulations that mimic the post-mortem degradation processes of ancient DNA,
then reconstructed methylation maps from the simulated deamination maps and
finally compared them to the original map and identified DMRs.
The simulation process starts with a methylation map, where the measured or
reconstructed methylation at position i is ψi and is assumed the true methylation.
Given that ni is the coverage at this position, we use the binomial distribution (1) to
randomly draw ti—the number of C’s that had become T’s through deamination.
The resulting ti’s were then used to compute the C → T ratios for each position,
smoothed and filtered using the same sliding window and thresholds used in the
original analysis, and linearly transformed to methylation percentages as explained
above (hereinafter, simulated methylation map, Supplementary Fig. 2a). Any
differences in methylation levels between the simulated map and the original
reference map stem from noise. Thus, running the same DMR-detection algorithm
described above on the simulated map vs. the reference map, enables an estimation
of the false discovery rate. We ran these simulations 100 times for each of the three
genomes (Altai Neanderthal, Denisovan, Ust’-Ishim) and determined the values of
the QþT and Q

T thresholds (see the Filtering DMRs section above) such that the
mean number of DMRs that are detected in the simulations is < 0.05 the number of
real DMRs detected (i.e., FDR < 0.05).
DMRs separating chimpanzees and humans. To identify DMRs that separate
chimpanzees from all human groups (both modern and archaic), we first compared
the chimpanzee WGBS bone methylome to each of two present-day WGBS maps
(those of Bone1 and Bone2). This was done by scanning the chimpanzee map using
a sliding window of 25 CpGs, in intervals of one CpG position. In each window, we
counted the number of methylated and unmethylated reads in each sample, and
computed a P-value using Fisher's Exact test. We then computed FDR-adjusted P-
values for each window, and discarded windows with FDR > 0.05 or where the
mean methylation difference (Δ) was below 0.5. We then merged overlapping
windows. This left 8040 DMRs between the chimpanzee and Bone1, and 12,666
DMRs between the chimpanzee and Bone2. Next, we intersected the two lists to
identify DMRs where the chimpanzee differs from the both present-day samples.
This left 6417 DMRs. Lastly, we compared the chimpanzee methylation levels to all
other human samples (modern and archaic) and filtered out DMRs where the
chimpanzee is found within the range of methylation levels observed in humans.
To do so, we followed the procedure described in the removing DMRs with high
within-group variability section below. This resulted in 2031 DMRs that separate
chimpanzees and humans.
Determining the lineages where DMRs originated. DMRs where Ust'-Ishim
differs from the Neanderthal and the Denisovan could either arose on the AMH
branch, or in the ancestor of Neanderthals and Denisovans. In order to allocate the
DMRs to the branch in which the change occurred, we used the chimpanzee DNA
methylation data.
First, we used the chimpanzee bone WGBS map. We defined the distance of a
DMR in hominin H to chimpanzee as the mean absolute difference in methylation,
dH;C ¼
P
i2DMR jψHi  ψCi j. Here, ψHi is the reconstructed methylation at the i’th
CpG in hominin H, and ψCi is the measured methylation in the same site in the
chimpanzee. For Ust'-Ishim-specific DMRs, we used the following procedure: (i) If
both archaic humans were closer to the chimpanzee, the DMR was placed on the
AMH branch. (ii) If Ust'-Ishim was closer than both archaic humans to the
chimpanzee, the DMR was placed on the branch of the ancestor of Neanderthals
and Denisovans. (iii) Otherwise, the DMR was discarded. Out of 5111 Ust'-Ishim-
specific DMRs, we could place 1729 DMRs on the AMH branch and 1255 on the
branch of the ancestor of Neanderthals and Denisovans. 1807 Ust'-Ishim-specific
DMRs were discarded due to inconclusive lineage assignment, and 320 had no data
in the chimpanzee WGBS map. For Neanderthal-specific DMRs, we discarded all
DMRs where Ust’-Ishim and the Denisovan were not found to be closer to the
chimpanzee than the Neanderthal. Out of 3107 Neanderthal-specific DMRs, 693
were placed on the Neanderthal branch, 2202 were deemed inconclusive and were
discarded, and 212 had no data in the chimpanzee WGBS map. Similarly, we
discarded Denisovan-specific DMRs where Ust’-Ishim and Altai Neanderthal were
not found to be closer to the chimpanzee than the Denisovan. Out of 1461
Denisovan-specific DMRs, 499 were placed on the Denisovan branch, 855 were
deemed inconclusive, and for 107 we had no data in the chimpanzee WGBS map.
We next developed a second, stricter, scheme by also using the chimpanzee
850K DNA methylation arrays datasets. As the probes cover just part of the CpGs
in a DMR, we need to adjust the DMR methylation level in order to allow a
meaningful comparison of 850K methylation data to full methylation maps. If we
mark by j the CpGs in a DMR that are covered by 850K methylation array (which
is a subset of all the CpGs in this DMR), and mark their total number by
J ¼Pj2DMR 1, then the methylation in the DMR as measured by the array is
m ¼ 1=J Pj2DMR ψarrayj , where ψarrayj is the methylation level measured at position




i be the methylation of this DMR as
computed from the full methylation map, where ψWGBSi is the methylation level




j be the methylation
as computed from the full methylation map when limited only to positions j. Then,
we correct the array methylation value m to:





This procedure was applied to DMRs covered by at least one probe (~65% of
DMRs). For the remaining ~35% of DMRs, we only used the WGBS chimpanzee
methylome. This approach was used in parallel with filtering DMRs using the
modern human 450K arrays (Supplementary Fig. 3, see next section).
There are pros and cons to each of these approaches. Using more chimpanzee
datasets allow for more informative process. However, 850K methylation array
probes are distributed unevenly across the genome. Although most DMRs are
covered by at least one probe (mean number of probes per DMR: 1.7, median: 1,
maximum: 64), many are nonetheless not covered. AMH
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On one hand, lineage assignment of DMRs for which we have array data is
more robust and less prone to misclassification. On the other hand, DMRs with
array data are more likely to be filtered out, as there is more power to detect
variability. This could potentially alter the genomic distribution of DMRs.
Therefore, we use both approaches throughout the paper. In analyses where it is
important to maintain an unbiased distribution of DMRs we only use the
chimpanzee WGBS map for polarization, and AMH bone WGBS maps for filtering
(see next chapter), whereas in analyses where it is more important to minimize
variability, or where we look at specific DMRs, we use the stricter approach. The
chimpanzee RRBS data was adjusted using the same technique. However, it was not
used for lineage assignment, but rather only as a source for additional information
on DMRs. This is because this protocol particularly targets unmethylated CpGs,
and is therefore too biased for lineage assignment.
Removing DMRs with high within-group variability. Our three-way DMR
detection algorithm above produces a list of DMRs where one of the three
hominins (Ust'-Ishim, Altai Neanderthal, or Denisovan) is significantly different
from the other two. However, such DMRs could stem from variability within any of
the groups, and in such cases cannot be regarded as truly differentiating between
the human groups. Some variability may be removed during the process described
above (see the Determining the lineages where DMRs originate section), but even
DMRs whose origin can be assigned to a particular lineage do not necessarily
represent fixed methylation changes. To filter out regions that are variable within
any of the human groups, or across all of them, we used two approaches. First, we
used the two modern human WGBS maps, and the I1583 reconstructed skull
methylation map. DMRs where the Neanderthal or Denisovan methylation levels
were found within the range of modern human methylation (i.e., Ust'-Ishim, the
two WGBS maps and I1583) were discarded. This left 1530 out of 1729 Ust'-Ishim-
derived DMRs (hereinafter, full AMH-derived DMRs), 1230 out of 1255 DMRs
where the Neanderthal and Denisovan are both derived, 692 out of 693 full
Neanderthal-derived DMRs, and 496 out of 499 Denisovan-derived DMRs.
The second approach adds to this the 52 450K methylation array samples, as
well as the three reconstructed methylation maps from teeth (i.e., Loschbour,
Stuttgart, and La Braña 1). As described above, using also methylation probes for
filtering DMRs provides more power, but can also introduce biases. Thus, this
filtering was used for most analyses, except those where unbiased genomic
distribution of DMRs is critical. Probe methylation data was corrected as described
in Eq. (2). Within AMH- and archaic-derived DMRs, a DMR was deemed fixed if
the Neanderthal and the Denisovan methylation levels both fell outside the range of
methylation across all modern human samples (reconstructed, WGBS and 450K
maps). Similarly, within Neanderthal-derived and Denisovan-derived DMRs, a
DMR was deemed fixed if the respective hominin fell outside the range of
methylation across all modern human samples and the other archaic hominin. This
approach yielded 873 AMH-derived DMRs (hereinafter referred to as AMH-
derived DMRs), 939 archaic-derived DMRs, 570 Neanderthal-derived DMRs, and
443 Denisovan-derived DMRs.
The limited number of archaic human methylation maps introduces asymmetry
in our ability to determine the level of fixation of DMRs along different lineages.
Whereas we used dozens of AMH skeletal samples, we have just a few archaic
samples. This provides us with the ability to better estimate the distribution of
methylation values within each DMR in AMH, and thus to determine how
significantly methylation values in other samples deviate from it. To enhance our
ability to estimate variability within archaic human lineages, we added to the
analysis the reconstructed methylation map of the Vindija Neanderthal. The
USER-treated portion of this genome (the portion amenable for methylation
reconstruction) was sequenced5 to a depth of 7×. Therefore, the methylation map
that could be reconstructed from this individual has a considerably lower
resolution compared to the other reconstructed maps used in this study (coverage
19× to 52×). Nevertheless, due to the reduced ability to detect variability along the
archaic human linages, we employed this map for additional variability filtering
along these lineages. DMRs where the Vindija Neanderthal clustered with the other
hominins, and not with the Altai Neanderthal (or not with either of the archaic
humans in the archaic-derived DMRs) were discarded. The number of DMRs
mentioned throughout this chapter already includes this filtering.
A general concern in working with DNA methylation data is that DMRs that
are specific to one group do not necessarily represent an evolutionary change, but
rather reflect a characteristic such as technology used to measure methylation,
tissue, sex, disease or age that is shared by individuals in this group and not by
others. We take two complementary approaches to ascertain that the DMRs we
report are not driven by these factors: (a) for the top DMGs, we match the samples
for the above factors and test whether the hypermethylation of AMHs is still
observed. To this end, we compared Ust’-Ishim (adult femur with no known
diseases, methylation map produced using our reconstruction method) to the
Vindija Neanderthal (adult femur with no known diseases, methylation map
produced using our reconstruction method), and we also compared 52 modern
human samples (adult femora, methylation array maps) to four chimpanzee
samples (adult femora, methylation array maps). In all cases, AMHs show
significant hypermethylation compared to the matched samples (Supplementary
Fig. 3c, d, see the Methylation in AMH, chimpanzee and Neanderthal femora
chapter for additional information). (b) throughout the pipeline, we take only
DMRs where one human group clusters completely outside the other groups
regardless of tissue, sex, disease, age or technology. Thus, these factors are unlikely
to drive the reported methylation changes. This approach is particularly useful in
AMH-derived DMRs, where each group of samples (i.e., AMH samples vs. archaic
and chimpanzee samples) include both males and females, juveniles and adults,
and they come from femora, ribs, tibia, skulls, and teeth. Thus, it is unlikely that the
DMRs that differentiate these groups reflect variability that stems from these
parameters43 (Fig. 1a–c). Archaic-derived DMRs and Neanderthal-derived DMRs
are also unlikely to reflect differences in the above parameters, as in these DMRs,
the Vindija Neanderthal sample (adult, femur bone) is clustered with the Altai
Neanderthal sample (juvenile/adult, phalanx), and not with AMHs, where most
samples are from femora of adult females. Denisovan-derived DMRs, on the other
hand, are more likely to stem from age or bone type differences than other types of
DMRs. This is because the Denisovan sample is the only finger bone, and it comes
from a child (6–13.5 years) (Supplementary Data 1). Thus, we cannot rule out the
possibility that some of the Denisovan-derived DMRs reflect finger-specific, rather
than lineage-specific methylation patterns. These DMRs could also possibly reflect
age-specific differences, but this is less likely, as the AMH I1583 sample9 and the
chimpanzee 850K samples are the same age group as the Denisovan (Denisovan:
6–13.5 years old, I1583: 6–10, chimpanzees: 10–13) but show different methylation
patterns than the Denisovan (Supplementary Data 1, Fig. 1).
Note that we do not generally expect the number of DMRs along a lineage to be
proportional to the length of the lineage, as this number is determined by several
factors. First, the statistical power to detect DMRs depends on coverage and
deamination levels. Thus, our ability to detect DMRs was lowest in the Denisovan,
and highest in Ust'-Ishim. Second, the ability to filter out within-population
variability was substantially higher along the AMH lineage, to which most samples
belong. While filtering out such variability, we also exclude variability that exists
across both AMH and archaic populations. This filtering also discards genomic
regions that are variable between sexes, bone types and regions where methylation
patterns tend to be more stochastic. Variability that exists exclusively along the
Neanderthal lineage was partially removed using the Vindija Neanderthal sample,
which comes from a different bone (femur vs. phalanx) and age (adult vs. juvenile/
adult). Along the Denisovan-lineage, on the other hand, such variability could not
be filtered out using our array of samples (Fig. 1).
We also repeated the Gene ORGANizer analyses (see the Gene ORGANizer
analysis section) after removal of 20 DMRs that overlap regions which were shown
to change methylation during osteogenic differentiation57. We show that the
enrichment of voice-affecting genes holds, and thus, the differentiation state of cells
in the samples is unlikely to explain the results we report.
Comparison to previous reports. We have previously reported that compared
to present-day humans, the HOXD cluster of genes is significantly hyper-
methylated in the Neanderthal and Denisovan samples4. Using the current
methylation maps, we show that this observation holds (Supplementary
Fig. 2b). Adding chimpanzee data, we see that similarly to AMHs, chimpanzee
samples are also hypomethylated compared to archaic humans. This suggests
that the hypermethylation arose along the archaic-human lineage. However, we
find that the Ust'-Ishim individual is an outlier among modern humans, and
that his methylation levels are closer to the Neanderthal than to modern
humans, as was also shown by Hanghøj et al.73. The Neanderthal and Ust'-
Ishim individuals are found >2 standard deviations from the mean observed
methylation in modern humans. This suggests that although the Neanderthal is
hypermethylated compared to almost all modern humans, she is not found
completely outside modern human variation. The Denisovan, on the other
hand, is found even further away, and significantly outside the other popula-
tions. Given this, the HOXD DMR was classified as Denisovan-derived (Sup-
plementary Data 2). The Ust'-Ishim remains include a single femur, and to our
knowledge, it was not compared morphologically to other humans. Thus,
further analysis is needed in order to determine whether the hypermethylation
of the Ust'-Ishim individual compared to other AMHs is manifested in mor-
phological changes as well. Moreover, as this DMR is classified as Denisovan-
derived, we cannot rule out the possibility that it is driven to some extent by
age or bone type differences.
Compared to the previously reported DMRs4, in this study we found four
times as many AMH-derived and archaic-derived DMRs (2805 full bone DMRs
compared to 891) and roughly twice as many Neanderthal- and Denisovan-
derived DMRs (440 and 598 compared to 295 and 307 in the Denisovan and
Neanderthal, respectively). The list of DMRs reported here cannot be directly
compared to our previous list of DMRs because of several key differences in the
analysis: (i) The previous study focused on DMRs that are invariable across
tissues, whereas here we focused on DMRs in skeletal tissues. In the previous
study, we were therefore able to extrapolate and find trends that extend beyond
the skeletal system, such as neurological diseases. In this paper we focus on the
skeletal system, hence the different appearance of the body map (Fig. 2b, c). (ii)
the current study used stricter thresholds for DMR detection, including a
minimum of 50 CpGs in each DMR (compared to ten CpGs previously), and a
requirement for physical overlap in the three-way DMR detection procedure.
(iii) In this study, the AMH reference is a reconstructed ancient map, whereas in
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the previous study the AMH reference, as well as the other tissues used for
filtering out noise, were mainly cultured cell lines with RRBS methylation maps.
When filtering DMRs along the lines of the previous study by taking only
DMRs with low inter-tissue variability in humans (STD < 10%), we indeed observe
similar trends. For example, when taking AMH-derived DMGs and analyzing their
expression patterns using DAVID's tissue expression tools, we found that the brain
is the most represented organ, with 51.5% of DMGs expressed in this organ (×1.28,
FDR= 2.6 × 10−4), and glial cells are the most over-represented cell type (×20.6,
but FDR > 0.05, UP_TISSUE DB, Supplementary Data 3). In fact, the brain is the
only significantly enriched organ in this analysis. Similarly, when analyzing the
GNF DB, we found that the subthalamic nucleus is the most enriched body part
(×1.60, FDR= 9.2 × 10−4), followed by additional brain regions, such as the
olfactory bulb (×1.54, FDR= 0.01), globus pallidus (×1.41, FDR= 0.04), and more
(Supplementary Data 3). Similar enrichment patterns of the brain can be observed
when analyzing expression patterns of all AMH-derived DMGs (Supplementary
Data 3). Finally, we also find that similarly to the previous report, these DMRs are
linked to diseases more often (23.1% compared to the genome average of 10.8%,
DAVID OMIM_DISEASE DB).
Computing correlation between methylation and expression. In order to
identify regions where DNA methylation is tightly linked with expression levels, we
scanned each DMR in overlapping windows of 25 CpGs (the window used for
smoothing the deamination signal). In each window we computed Pearson’s cor-
relation between DNA methylation levels and expression levels of overlapping
genes as well as the closest genes upstream and downstream genes, across 21
tissues33. For each DMR, we picked the window with the best correlation (in
absolute value) and computed regression FDR-adjusted P-value. DMRs that
overlap windows with FDR < 0.05 were considered to be regions where methylation
levels are significantly correlated with expression levels. Ninety such DMRs were
found among the skeletal AMH-derived DMRs, 93 among the archaic human-
derived DMRs, 40 among Neanderthal-derived DMRs, and 19 among Denisovan-
derived DMRs.
As no expression data were available for Ust'-Ishim, Bone1 and Bone2, we
approximated their NFIX expression level by taking the average of NFIX expression
from three osteoblast RNA-seq datasets that were downloaded from GEO accession
numbers GSE55282, GSE85761, and GSE78608. RNA-seq data for chondrocytes
was downloaded from the ENCODE project, GEO accession number GSE78607
and plotted against measured methylation levels in primary chondrocytes (see the
Human primary chondrocyte validation chapter). Notably, even though the
expression and methylation data come from different individuals, plotting them
against one another positions them only ~one standard deviation from the
expression value predicted by the regression line (Fig. 5b). Future studies providing
RNA expression levels for the laryngeal skeleton and vocal folds might provide
further information on the methylation-expression links of these genes.
Studying the function of DMGs. Gene ontology and expression analyses were
conducted using Biological Process and UNIGENE expression tools in DAVID,
using an FDR threshold of 0.05.
Gene ORGANizer analysis. Similarly to sequence mutations, changes in regula-
tion are likely to be unequally distributed across different body systems, owing to
negative and positive selection, as well as inherent traits of the genes affecting each
organ. Thus, we turned to investigate which body parts are affected by the DMGs.
To this end, we ran the lists of DMGs in Gene ORGANizer11, which is a tool that
links genes to the organs they affect, through known disease and normal pheno-
types. Thus, it allows us to investigate directly the phenotypic function of genes, to
identify their shared targets and to statistically test the significance of such
enrichments. We ran the lists of DMGs in the ORGANize option using the default
parameters (i.e., based on confident and typical + non-typical gene-phenotype
associations).
When we ran the list of skeletal AMH-derived DMRs, we found 11 significantly
enriched body parts, with the vocal folds and the larynx being the most enriched
parts (×2.11 and ×1.68, FDR= 0.017 and FDR= 0.046, respectively). Most other
parts belonged to the face (teeth, forehead, lips, eyelid, maxilla, face, and jaws), as
well as the pelvis and nails (Fig. 2c, d and Supplementary Data 4). For archaic-
derived DMGs, the lips, limbs, jaws, scapula, and spinal column were enriched
(Supplementary Fig. 4e, Supplementary Data 4). The Neanderthal-derived and
Denisovan-derived DMG lists did not produce any significantly enriched organs,
but the immune system was significantly depleted within Neanderthal-derived
DMRs (×0.67, FDR= 0.040).
In order to examine whether such trends could arise randomly from the
reconstruction method, we repeated the analysis on the previously described
100 simulations. We ran all simulated DMGs (4153) in Gene ORGANizer and
found that no enrichment was detected, neither for voice-related organs (vocal
folds: ×0.99, FDR= 0.731, larynx: ×1.02, FDR= 0.966, FDR= 0.966), nor for any
other organ.
Validation of face and larynx enrichment in Gene ORGANizer. To test whether
the enrichment of the face and larynx could be attributed to the fact that the
analyses are based on skeletal tissues, we tested whether the proportion of genes
related to the face, larynx, vocal folds, and pelvis within AMH-derived skeleton-
related DMGs is higher than expected by chance. Out of 100 skeleton-related
DMGs, 31 genes are known to affect the voice, 34 affect the larynx, 87 affect the
face, and 65 affect the pelvis, whereas genome-wide these proportions are sig-
nificantly lower (14.2%, 20.2%, 70.0%, 52.4%, P= 1.0 × 10−5, P= 1.3 × 10−3, P=
2.1 × 10−3, P= 0.03, for vocal folds, larynx, face, and pelvis, respectively, hyper-
geometric test). For additional validation tests, see main text.
Genes associated with craniofacial features were taken from the GWAS-catalog
(version 2019-04-21), using a threshold of P < 10−8. The following features were
used: dental caries, cleft palate, facial morphology, intracranial volume, cleft palate
(environmental tobacco smoke interaction), cranial base width, craniofacial
macrosomia, facial morphology (factor 1, breadth of lateral portion of upper face),
facial morphology (factor 10, width of nasal floor), facial morphology (factor 11,
projection of the nose), facial morphology (factor 12, vertical position of sublabial
sulcus relative to central midface), facial morphology (factor 14, intercanthal
width), lower facial height, nose morphology, nose size, tooth agenesis (maxillary
third molar), tooth agenesis (third molar), facial morphology traits (multivariate
analysis), lower facial morphology traits (ordinal measurement), lower facial
morphology traits (quantitative measurement), middle facial morphology traits
(quantitative measurement), and upper facial morphology traits (ordinal
measurement). We then tested their overlap with DMGs. Genes associated with
craniofacial features in the GWAS catalog significantly overlapped DMGs
compared to the fraction expected by chance (5.17×, P= 3.4 × 10−4,
hypergeometric test). As a control, we then tested how this 5-fold enrichment
compares to non-craniofacial features. We used blood-related GWAS as a
representative of general non-craniofacial GWAS. We extracted from the GWAS
catalog 22 blood-related traits (the same number as extracted for craniofacial
features), by taking the first 22 traits that appear in a search for the term blood and
applying a threshold of P < 10−8. We then used these genes as a background
control for the craniofacial enrichment. We observed a 3.86× enrichment of DMGs
with regard to craniofacial-associated vs. non-craniofacial-associated genes (P=
0.01, chi-square test).
Additionally, we conducted a permutation test on the list of 129 AMH-derived
DMGs that are linked to organs on Gene ORGANizer, replacing those that are
linked to the skeleton with randomly selected skeleton-related genes. We then ran
the list in Gene ORGANizer and computed the enrichment. We repeated the
process 100,000 times and found that the enrichment levels we observed within
AMH-derived DMGs are significantly higher than expected by chance for the
laryngeal and facial regions, but not for the pelvis (P= 8.0 × 10−5, P= 3.6 × 10−3,
P= 8.2 × 10−4, and P= 0.115, for vocal folds, larynx, face and pelvis, respectively,
permutation test, Supplementary Fig. 4b–e).
Potentially, longer genes have higher probability to overlap DMRs. Indeed,
DMGs tend to be longer (148 vs. 39 kb, P= 9.9 × 10−145, t-test). We thus checked
the possibility that genes affecting the larynx and face tend to be longer than other
genes, and are thus more likely to contain DMRs. We found that length of genes
could not be a factor explaining the enrichment within genes affecting the larynx,
as these genes tend to be shorter than other genes in the genome (mean: 62.5 vs.
73.2 kb, P= 0.001, t-test). Genes affecting the face, on the other hand, tend to be
longer than other genes (mean: 77.1 vs. 65.6 kb, P= 4.6 × 10−5, t-test). To examine
if this factor may underlie the enrichment we observe, we repeated the analysis
using only DMRs that are found within promoter regions (5 kb upstream to 1 kb
downstream of TSS), thus eliminating the gene length factor. We found that the
genes where such DMRs occur are still significantly associated with the face (P=
0.036, Fisher's exact test). We next repeated the promoter DMR analysis for all
genes and compared the Gene ORGANizer enrichment levels in this analysis to the
genome-wide analysis. We observed very similar levels of enrichment (2.02×,
1.67×, and 1.24×, for vocal folds, larynx, and face, respectively, albeit FDR
values >0.05 due to low statistical power). Importantly, AMH-derived DMGs also
do not tend to be longer than DMGs on the other branches (148 vs. 147 kb, P=
0.93, t-test). Together, these analyses suggest that gene length does not affect the
observed enrichment in genes affecting the face and larynx.
Additionally, to test whether cellular composition or differentiation state could
bias the results, we ran Gene ORGANizer on the list of DMGs, following the
removal of 20 DMRs that are found <10 kb from loci where methylation was
shown to change during osteogenic differentiation57. We found that genes affecting
the voice and face are still the most over-represented (2.13×, 1.71×, and 1.27×,
FDR= 0.032, FDR= 0.049, and FDR= 0.040, for vocal folds, larynx, and face,
respectively, Supplementary Data 4).
We also investigated the possibility that (for an unknown reason) the DMR-
detection algorithm introduces positional biases that preferentially identify DMRs
within genes affecting the voice or face. To this end, we simulated stochastic
deamination processes along the Ust'-Ishim, Altai Neanderthal, and Denisovan
genomes, reconstructed methylation maps, and ran the DMR-detection algorithm
on these maps. We repeated this process 100 times for each hominin and found no
enrichment of any body part, including the face, vocal folds, or larynx (1.07×,
1.07×, and 1.04×, respectively, FDR= 0.88 for vocal folds, larynx, and face,
permutation test). Perhaps most importantly, none of the other archaic branches
shows enrichment of the larynx or the vocal folds. However, archaic-derived
DMGs show over-representation of the jaws, as well as the lips, limbs, scapulae,
and spinal column (Supplementary Fig. 4e, Supplementary Data 4). In addition,
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DMRs that separate chimpanzees from all humans (archaic and modern,
Supplementary Data 2) do not show over-representation of genes that affect the
voice, larynx, or face, compatible with the notion that this trend emerged along the
AMH lineage. We also sought to test whether the larynx and vocal folds, which we
found to be significantly enriched only along the AMH lineage, are also enriched
when compared to the other lineages. We ran a chi-squared test on the fraction of
vocal folds-affecting and larynx-affecting AMH-derived DMGs (25 and 29,
respectively, out of a total of 120 organ-associated DMGs), compared to the
corresponding fraction in the DMGs along all the other lineages (42 for vocal folds,
49 for larynx, out of a total of 275 organ-associated DMGs). We found that both
the larynx and vocal folds are significantly enriched in AMHs by over 50%
compared to the other lineages (1.57× for both, P= 0.0248 and P= 0.0169 for
vocal folds and larynx, respectively, chi-squared test).
Furthermore, we added a human bone reduced representation bisulfite
sequencing (RRBS) map, and produced a RRBS map from a chimpanzee infant
unspecified long bone (Supplementary Data 1). RRBS methylation maps include
information on only ~10% of CpG sites, and are biased towards unmethylated sites.
Therefore, they were not included in the previous analyses. However, we added
them in this part as they originate from a chimpanzee infant and a present-day
human that is of similar age to the Denisovan (Supplementary Data 1), allowing
sampling from individuals that are younger than the rest. Repeating the Gene
ORGANizer analysis after including these samples in the filtering process, we
found that the face and larynx are the only significantly enriched skeletal regions,
and the enrichment within voice-affecting genes becomes even more pronounced
(2.33×, FDR= 7.9 × 10−3, Supplementary Data 4).
We also examined if pleiotropy could underlie the observed enrichments. To a
large extent, the statistical tests behind Gene ORGANizer inherently account for
pleiotropy11, hence the conclusion that the most significant shared effect of the
AMH-derived DMGs is in shaping vocal and facial anatomy is valid regardless of
pleiotropy. Nevertheless, we tested this possibility more directly, estimating the
pleiotropy of each gene by counting the number of different Human Phenotype
Ontology (HPO) terms that are associated with it across the entire body19. We
found that DMGs do not tend to be more pleiotropic than the rest of the genome
(P= 0.17, t-test), nor do differentially methylated voice-affecting and face-affecting
genes tend to be more pleiotropic than other DMGs (P= 0.19 and P= 0.27,
respectively, t-test).
Next, we tested whether the process of within-lineage removal of variable DMRs
and the differential number of samples along each lineage biases the Gene
ORGANizer enrichment analysis. To do so, we analyzed the pre-filtering DMRs
along each lineage. We detect very similar trends to the post-filtering analysis, with
the laryngeal and facial regions being the most significantly enriched within AMH-
derived DMRs (1.58×, 1.44×, and 1.21× to 1.31× for the vocal folds, larynx and
different facial regions, respectively, FDR < 0.05), and for archaic-derived DMRs,
we detect no enrichment of the laryngeal region (FDR= 0.16 and FDR= 0.43 for
the vocal folds and larynx, respectively), and the most enriched regions are the face,
limbs, and urethra. With the exception of the urethra, these results are very similar
to the results reported for the filtered DMRs, suggesting that the process of within-
lineage removal of variable DMRs and the differential number of samples along
each lineage does not bias the enrichment results.
Overall, we observe that AMH-derived DMGs across all 60 AMH samples are
found outside archaic human variability, regardless of bone type, disease state, age,
or sex, and that chimpanzee methylation levels in these DMGs cluster closer to
archaic humans than to AMHs, suggesting that these factors are unlikely to
underlie the observed trends. Finally, we tested whether the filtering process in
itself might underlie the observed trends. To this end, we re-ran the entire pipeline
on Neanderthal-derived and Denisovan-derived DMGs, while applying to them all
the filters as if they were Ust’-Ishim DMGs. This resulted in substantially fewer loci
(89 for the Neanderthal and 50 for the Denisovan), which limits statistical power,
but can still be used to examine whether there are any trends of enrichment similar
to those observed in AMHs. We found no evidence that the filtering process could
drive the enrichment of the vocal or facial areas: within Neanderthal-derived loci,
filtered as if they were Ust’-Ishim-derived, we found that the vocal folds were
ranked only 18th, with a non-significant enrichment of 1.27× (FDR= 0.815,
compared to an enrichment of 2.11× within AMH-derived DMGs). The larynx was
ranked 76th and showed a non-significant depletion of 0.87× (FDR= 0.783), and
the face was ranked 31st, with a non-significant enrichment of 1.09× (FDR=
0.815). Within Denisovan-derived loci, filtered as if they were Ust’-Ishim-derived,
none of the loci were linked to the vocal folds nor to the larynx (FDR= 0.535 and
FDR= 0.834, respectively), and the face was ranked 30th (1.29x, FDR= 0.535,
Supplementary Data 4). This test suggests that the filtering process in itself is very
unlikely to underlie the enrichment of the vocal and facial parts within AMH-
derived DMGs.
Next, we applied the Neanderthal/Denisovan filters to the Ust’-Ishim-derived
loci. This resulted in 792 loci. We found that the vocal folds remained the most
enriched body part (1.76×, FDR= 0.032), the larynx was marginally significant
(1.53×, FDR= 0.0502), and the facial region was significantly enriched too (e.g.,
cheek and chin ranked 2nd, 3rd within significantly enriched body parts, 1.66× and
1.63×, FDR= 0.031 and FDR= 0.013, respectively, Supplementary Data 4).
Importantly, we do not rule out the option that extensive regulatory changes in
genes related to vocal and facial anatomy might have occurred along the
Neanderthal and Denisovan lineages as well. Indeed, as we report in
Supplementary Fig. 4e, parts of the face are enriched within Archaic-derived
DMGs. However, we currently see no substantial evidence supporting this.
Importantly, the link between genetic alterations and phenotypes related to the
voice is complex. Some brain-related disorders (i.e., clinical disorders that affect the
brain) result in alterations to the voice, the mechanism in which is very difficult to
pin down. Although the mechanism leading to voice alterations (either in its pitch,
timbre, volume, or range) in some of the genes we report is unknown, many of the
disorders are skeletal, suggesting the mechanism is related to anatomical changes to
the vocal tract. Such changes could also affect more primary functions of the
larynx, such as swallowing and breathing. However, the enrichment we observe in
Gene ORGANizer shows these genes were also shown to drive vocal alterations in
the disorders they underlie11,19. Voice and speech alterations were also shown to be
driven by cultural, dietary and behavioral changes affecting bite configuration74.
Here too, these factors are unlikely to underlie the vocal alterations in the genes we
report, as individuals from the same family as the individual with the disorder, who
do not carry the dysfunctional allele, were not reported to present any vocal
phenotypes.
The larynx is an organ which is primarily involved in breathing and swallowing
in mammals. In humans, the larynx is also used to produce complex speech, but
not every change to the larynx necessarily affects speech. Despite these additional
functions, the genes reported by Gene ORGANizer and HPO were specifically
associated with voice alterations, directly or indirectly, suggesting that although
they could have additional effects, their effect on the voice is their most shared
function.
Overlap with enhancer regions. To further test whether the AMH-derived DMRs
overlap skeletal regulatory regions, we examined the previously reported 403,968
human loci, where an enrichment of the active enhancer mark H3K27ac was
detected in developing human limbs (E33, E41, E44, and E47)75. Each DMR was
allocated a random genomic position in its original chromosome, while keeping its
original length and matching the distribution of GC-content and CpG density
between the original and permutated lists. GC-content and CpG density matching
was done by matching a 10-bin histogram of the original and permutated lists. This
was repeated for 10,000 iterations. We found that AMH-derived DMRs overlap
limb H3K27ac-enriched regions ~2× more often than expected by chance (610
overlapping DMRs, compared to 312.4 ± 21.7, P < 10−4, permutation test).
SOX9 upstream putative enhancer coordinates used in Fig. 4b were taken
from13,14,23,76,77.
Computing the density of changes along the genome. We computed the density
of derived CpG positions along the genome in two ways. First, we used a 100 kb
window centered in the middle of each DMR and computed the fraction of CpGs
in that window which are differentially methylated (i.e., are found within a DMR).
Second, for the chromosome density plots, we did not center the window around
each DMR, but rather used a non-overlapping sliding 100 kb window starting at
position 1 and running the length of the chromosome.
NFIX, COL2A1, SOX9, ACAN, and XYLT1 phenotypes. The vocal tract and
larynx affecting genes presented in this paper show involvement in laryngeal
cartilage and soft tissue phenotypic variation. Clinical phenotypes can be of high
severity, with substantial impacts on normal breathing functions, to the point
where the cause of death is due to respiratory distress. SOX9 and NFIX are often
associated with laryngomalacia11,19 (Supplementary Data 5), a collapse of the
larynx due to malformation of the laryngeal cartilaginous framework and/or
malformed connective tissues, particularly during inhalation. Patients with muta-
tions in COL2A1 often show backwards displacement of the tongue base11,19. Less
severe phenotypes of the reported genes include variation of voice quality in the
form of pitch variation (high in patients suffering from XYLT1 mutations) and
sometimes hoarseness of the voice (reported for some patients with mutations of
ACAN, Supplementary Data 5)11,19. Whether this is due to variation of the vocal
tract and laryngeal anatomy influenced by the ACAN mutation or due to a scaled
down vocal tract size in the case of the XYLT1 mutation which also causes pri-
mordial dwarfism is not yet clear.
NFIX phenotypes. Skeletal phenotypes that are associated with the
Marshall–Smith syndrome were extracted from the Human Phenotype Ontology
(HPO)19. Non-directional phenotypes (e.g., irregular dentition) and phenotypes
that are expressed in both directions (e.g., tall stature and short stature) were
removed.
Mutations in NFIX have also been linked to the Sotos syndrome. However,
NFIX is not the only gene that was linked to this syndrome; mutations in NSD1
were also shown to drive similar phenotypes52. Therefore, it is less relevant in
assessing the functional consequences of general shifts in the activity levels of
NFIX. Nevertheless, it is noteworthy that in the Sotos syndrome too, most
symptoms are a mirror image of the Neanderthal phenotype (e.g., prominent chin
and high forehead).
Comparing gene expression between AMH and mouse. Ninety-three appen-
dicular skeleton samples were used to compare expression levels of NFIX, SOX9,
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ACAN, and COL2A1 in human and mouse: 1. Five Human expression array data of
iliac bones78, downloaded from ArrayExpress accession number E-MEXP-2219. 2.
Eighty-four human expression array of iliac bones, downloaded from ArrayExpress
accession number E-MEXP-1618. 3. Three mouse expression array data of femur
and tibia bones, downloaded from ArrayExpress accession number E-GEOD-
61146. 4. One mouse RNA-seq of a tibia bone, downloaded from supplementary
data. Expression values were converted to percentiles, according to each gene
expression level compared to the rest of the genome across each sample (Fig. 5c).
Methylation in AMH, chimpanzee, and Neanderthal femora. To check whether
the AMH hypermethylation of SOX9, ACAN, COL2A1, XYLT1, and NFIX could be
a result of variability between bone types, we compared the four chimpanzee femur
850K methylation arrays to the 52 present-day femur 450K methylation arrays. We
took probes within AMH-derived DMRs that appear on both arrays. We found
that these genes are consistently hypermethylated in AMHs (P= 1.6 × 10−7, t-test),
with 38 probes showing >5% hypermethylation in AMH, whereas only eight probes
show such hypermethylation in chimpanzees (Supplementary Fig. 5d). Therefore,
even when comparing methylation from the same bone, same sex, same devel-
opmental stage, measured by the same technology, and across the same positions,
AMH show consistent hypermethylation across all of these DMGs.
Similarly, when comparing the DMRs in SOX9, ACAN, COL2A1, XYLT1, and
NFIX between the Ust'-Ishim and Vindija Neanderthal samples, the Vindija
Neanderthal sample is consistently hypomethylated compared to the Ust'-Ishim
individual (P= 1.2 × 10−5, Supplementary Fig. 5c, t-test). Both of these samples
were extracted from femora of adult individuals, and methylation was
reconstructed using the same technology. This suggests that the hypermethylation
of AMHs compared to Neanderthals is unlikely to be driven by age or bone type,
and rather reflects evolutionary shifts.
Scanning SOX9 for mutations altering NFI binding motifs. To examine whether
the changes in regulation of SOX9 could possibly be explained by changes in the
binding sites of NFI proteins, we searched for the NFI motif along the gene body
and the 350 kb upstream region of SOX9. We looked for NFI motifs that exist in
the genomes of the Altai and Vindija Neanderthal, as well as in the Denisovan, but
were abolished in AMHs. We did not find any evidence of such substitutions.
Comparison to divergent traits between Neanderthals and AMHs. To further
investigate potential phenotypic consequences of the DMGs we report, we
probed the HPO database19 and compared these HPO phenotypes to known
morphological differences between Neanderthals and modern humans32. To
compile a list of traits in which Neanderthals and AMHs differ, we reviewed key
sources that surveyed Neanderthal morphology summarized in Aiello, L. and
Dean12. We identified traits in which Neanderthals are found completely outside
AMH variation, as well as traits where one group is significantly different from
the other, but the distribution of observed measurements partially overlap. Non-
directional traits (i.e., traits that could not be described on scales such as higher/
lower, accelerated/delayed etc.) were not included, as could not be paralleled
with HPO phenotypes. The compiled list included 107 phenotypes, 75 of which
have at least one equivalent HPO phenotype (4.8 on average). For example, the
HPO phenotype Taurodontia (HP:0000679) was linked to the trait Taurodontia,
and the following HPO phenotypes were linked to the trait Rounded and robust
rib shafts: broad ribs (HP:0000885), hypoplasia of first ribs (HP:0006657), short
ribs (HP:0000773), thickened cortex of long bones (HP:0000935), thickened ribs
(HP:0000900), thin ribs (HP:0000883), thoracic hypoplasia (HP:0005257). For
each skeleton-affecting phenotype, we determined whether it matches a known
morphological difference between Neanderthals and AMHs32. For example,
Hypoplastic ilia (HPO ID: HP:0000946) was marked as divergent because in the
Neanderthal the iliac bones are considerably enlarged compared to AMHs12. We
then counted for each gene (whether DMG or not) the fraction of its associated
HPO phenotypes that are divergent between Neanderthals and AMHs. We
found that four of the top five most differentially methylated skeletal genes
(XYLT1, NFIX, ACAN, and COL2A1) are in the top 100 genes with the highest
fraction of divergent traits between Neanderthals and AMHs (out of a total of
1,789 skeleton-related genes). In fact, COL2A1, which is the top ranked DMR
(Supplementary Data 2), is also the gene that is overall associated with the
highest number of derived traits (63) (Supplementary Data 7). This suggests that
these extensive methylation changes are possibly linked to phenotypic diver-
gence between archaic and AMHs.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All sequencing and methylation data generated in this work have been deposited in
NCBI’s Gene Expression Omnibus under GEO accession number GSE96833. All other
data and materials are contained in the paper and its supplementary information or
available upon request.
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